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EPIDEMIOLOGY
Colorectal cancer is one of the leading causes of death and accounts for approximately 300.000 
new cases in Europe and the USA.1 In the Netherlands in 2005 over 10.000 patients were diag-
nosed with colorectal carcinoma.2 Rectal cancer approximately constitutes 25% of all colorectal 
carcinomas. Almost half of all patients eventually die from the disease.
Majority of rectal cancers develop from benign pre-neoplastic lesions: the adenomatous polyps 
or adenomas. Progression from a benign adenoma to a malignant carcinoma passes through 
a series of well-defined histological stages, which is referred to as the adenoma-carcinoma 
sequence.3 Because of the implementation of population-based screening programs, the 
number of patients with early staged rectal carcinomas is likely to increase in the near future.4 
There has been an impressive evolution in the therapy for rectal cancer. In 1826 Lisfranc was 
credited the first person to remove the cancer bearing segment of the rectum; he did so using 
a transanal approach.5 In that era, the only feasible treatment of rectal cancer consisted of a 
colostomy to relieve obstruction, as first described by Amussat in 1839.6 In 1885, Kraske and col-
leagues approached rectal cancer using a trans-sacral approach, which is removing the coccyx 
and distal sacrum, with preservation of the anus and muscles.7 In 1908 the abdomino-perineal 
resection (APR) was reported, which can be attributed largely to Ernest Miles.8 After observing 
a high incidence of cancer recurrence in patients undergoing local treatment for rectal cancer, 
he developed the concept of radical rectal excision. Miles postulated the lymphatic spread 
of rectal cancer was directed superiorly and that this surgery allowed complete resection of 
the anorectum and draining lymphatics. The APR procedure, which gained acceptance largely 
because it was oncologically sound and successful, has led to the cure of many patients with 
rectal tumors. Its feasibility was further enhanced by the availability of blood transfusion, allow-
ing this radical surgery to become the most popular method of dealing with rectal cancer by 
1947. In 1923 Hartmann described a two-stage procedure for upper rectal cancer.9 After an 
artificial anus was constructed, during the second operation the cancer bearing segment was 
excised and the closed upper rectum was reperitonealized. Dixon established the safety of the 
anterior resection in the late 1940`s, but this approach was mainly limited to the treatment of 
upper rectal cancer until the 1970`s.10 At that time, the introduction of circular stapling devices 
facilitated the technical possibility of low rectal anastomosis and even colo-anal anastomosis. 
This technological advance, along with the recognition that distal margins of < 2 cm did not 
compromise outcome, dramatically changed the approach to many patients.
The most recent advance was the introduction of the concept of total mesorectal excision 
(TME). This technique has meanwhile shown, by Heald et al and many others, to minimize local 
recurrence, to allow even ultralow resections with colo-anal anastomosis to be accepted as 
appropriate operations, resulting in survival rates comparable with APR, without the need for 







relatively high rate of complications, including anastomotic leakage, genito-urinary dysfunc-
tion, defecation disorders and up to 4% mortality.  
More or less parallel with the advent of TME, others focused on the improved possibilities of 
local excision (LE) for rectal cancer, initially as a palliative procedure, but now even with cura-
tive intent in selected tumors.  The technique most commonly used is the transanal approach, 
according to Parks.12 This however suffers from poor exposure and inadequate access to 
lesions, especially in the upper rectum, resulting in recurrence rates up to 60 percent.13, 14 
Trans-sacral (Kraske) and trans-sphincteric (Mason) approaches are technically demanding and 
invasive, resulting in high morbidity (up to 40 percent), often severe and mortality rates of 1-5 
percent.15-22 Moreover, recurrence rates range between 12 to 25 percent.
Transanal endoscopic microsurgery (TEM) is a recently introduced minimal invasive technique 
for local excision of rectal tumors.23 In adenomas TEM is superior in safety and local control 
and tumors in the entire rectum can be treated and therefore TEM is the method of choice.24-27
In a recent report by You et al, from 1989 to 2003 the rate of LE for T1 rectal carcinomas in the 
USA increased from 26.6 to 43.7% and from 5.8 to 16.8% for T2 rectal carcinomas.28 This increas-
ing role is ultimately reflected by several national guidelines, propagating selected tumors 
suitable for LE.29 In many studies it is emphasized LE is safe regarding morbidity and mortality, 
especially compared to (conventional) radical surgery. The main question to be answered how-
ever is whether LE is justified from an oncologic point of view. The safety of a local procedure 
has to be balanced against the higher risk of local recurrences and/or worsened survival. In T2 
rectal carcinomas, both local recurrence rates and survival rates after LE are worse compared 
to radical surgery, and therefore LE is considered a valid option only in palliative procedures.
LOCAL EXCISION OR RADICAL SURGERY
Radical surgery (RS) for T1 rectal carcinomas leads to excellent results.30 Local recurrence rates 
are invariably low, ranging from zero to six percent. Five and 10-year survival rates are as high 
as 82 and 68%, respectively. Can similar results be achieved by applying LE according to Parks 
for T1 rectal carcinomas? No randomized study has been performed, but several comparative 
studies have been published upon this issue.14, 28, 31-34 (Table 1) The earlier mentioned study 
of You et al. reports upon outcome after LE according to Parks (LE) in comparison to radical 
surgery (RS). In the LE group patients were older and tumors were smaller and located more 
distal.  LE was significantly safer, as expressed by the lower morbidity rate (5.6% vs. 14.6%, p < 
0.001). The vast majority of tumors were excised microscopic radical (R0) in both groups (95% 
vs. 99%). Regarding oncologic outcomes, 5-years local recurrence rates after R0 excision were 
12.5% after LE and 6.9% after RS (p = 0.003). Overall survival rates were comparable (LE 77.4%, 
RS 81.7%, p = 0.09), however disease specific survival rates were significantly lower after LE 
(93.2% vs. 97.2%, p = 0.004).
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A prospective multicenter observational study was performed by Ptok et al.34 In their study, 
selection was made based on histopathological criteria. In case of a low-risk T1 rectal carci-
noma, that is well or moderately differentiated, radically excised, smaller than three centimeters 
and without lymph vascular invasion, LE is presumed curative. Both LE according to Parks and 
TEM were performed and not analyzed separately. After LE local recurrence rate was higher (LE 
6%, RS 2%; p = 0.049), although tumor-free survival was comparable (LE 91%, RS 92%; p = 0.39).
Mellgren et al. reported upon outcome after LE for 69 T1 rectal carcinomas, in comparison to 
30 T1N0 rectal carcinomas treated by RS.14 Neither group received neoadjuvant chemoradia-
tion. In the LE group, tumors were significantly smaller and located more distally. After LE local 
recurrence rates were higher (18 versus zero percent; p = 0.03), as well as overall recurrence 
rates, although the latter not significantly (21 versus nine percent; p = 0.54). Five-year survival 
rates were comparable (LE 72%, RS 80%; p = 0.50). Another study was performed by Bentrem 
et al.32 In their study 319 consecutive patients with T1 rectal carcinomas were treated by LE 
according to Parks (n=151) or RS (n=168) over a 17-year period. In the RS group 18% of tumors 
were node-positive; no tumor selection regarding differentiation grade and/or lymph vascular 
invasion was applied. Again, in the LE group tumors were smaller and located more distally. 
After LE adjuvant radiotherapy was given in case of close margins (n=11) or high-risk pathol-
ogy (n=5). None of the patients received adjuvant systemic chemotherapy. After RS, in case of 
positive lymph nodes adjuvant radiotherapy (n=16) or chemotherapy (n=29) was given. At five 
years, local recurrence rate after LE was 15% versus three percent after RS (p = 0.0001). Overall 
recurrence rates also differed significantly (LE 23%, RS six percent; p < 0.001). Disease-specific 
Table 1. Comparative series of local excision according to Parks (LE) versus radical surgery (RS) for T1 rectal 
carcinomas.
Author LE vs. RS 
(no.)
R0:
















69 vs 30 100 vs 100 18 vs 0‡ 21 vs 9 72 vs 80 DSS: 95 vs. 95
Nascimbeni
(2004)31
70 vs 74 NS 6.6 vs 2.8‡ 21 vs 10‡ 72 vs 90‡
DSS: 89 vs. NS
DFS: 67 vs. 84‡
Bentrem
(2005)32
151 vs 168 NS 15 vs 3‡ 23 vs 6‡ 89 vs. 93* DSS: 93 vs. 97*
Endreseth
(2005)33
35 vs 256 83 vs 100‡ 12 vs 6‡ 12 vs 13 70 vs. 80*‡ DFS: 64 vs. 77*‡
Ptok
(2007)34
105 vs 312 100 vs 100 6 vs 2‡ 10 vs 6 84 vs 92 DFS: 91 vs 92
You
(2007)28
601 vs 493 95 vs 99 12.5 vs 6.9‡ 16 vs 10‡ 77 vs. 82 DSS: 93 vs. 97‡
R0= microscopic radical excision, LR= local recurrence, OR= overall recurrence, DSS= disease specific sur-
vival, DFS= disease free survival, OS= overall survival
Survival rates are 5-years, unless otherwise specified; ‡ statistically significant (p < 0.05), NS= not stated; 







and overall survival rates were similar for LE and RS. Of all recurrences after LE, 77% could be 
resected radically, compared to 50% of local recurrences after RS. A nationwide, prospective 
study was performed by Endreseth et al.33 They analyzed outcome of 291 T1M0 rectal carcino-
mas treated by LE according to Parks (n=35) or RS (n=256). In the LE group patients were older 
and tumors were smaller and located more distally and only in the minority of tumors with LE a 
R0 (microscopic negative) excision margin could be obtained. After excluding R2 (macroscopic 
irradical) procedures, local recurrence rate after LE was still significantly higher compared to 
RS (12 versus six percent; p = 0.01). Overall survival (70 versus 80%; p = 0.04) and disease free 
survival (64 versus 77 percent; p = 0.01) were significantly worse after LE.
Interpretation of all above mentioned studies remains difficult, as a selection bias may have 
been introduced, as expressed by the smaller, more distal located tumors treated by LE. Never-
theless, in all studies a significant proportion of tumors recurred, although in majority of studies 
this seems not to influence survival rates.
TEM OR PARKS
Can results be improved by using another technique for local excision? In rectal adenomas it 
was shown that application of transanal endoscopic microsurgery (TEM) results in lower recur-
rence rates compared to LE according to Parks.26, 27 Can these results be extrapolated for T1 
rectal carcinomas? Four studies were retrieved in which TEM was compared with another type 
of surgery (LE according to Parks and/or RS). (Tables 2 and 3)
Only one randomized controlled trial for clinical T1 rectal carcinomas has been performed.35 
This trial included 52 patients with presumed T1 rectal carcinomas, well or moderately differen-
tiated, during an eight-year period. Patients were randomized to TEM or RS. Post-inclusion two 
patients were excluded because of a later pTNM staging. Twenty-four patients were treated 
using the TEM technique and 26 patients underwent anterior resection. Both groups were 
comparable in age and gender distribution. TEM proved to be the safest technique in the early 
postoperative period and patients required less postoperative analgesics. With median follow-
up more than 40 months, local recurrence rate after TEM was 4.1 percent (1/24). In the RS group 
no local recurrence occurred. Five-year procedure specific survival rates were 96 percent for 
both groups.
Langer et al. reported (retrospectively) upon outcome after TEM in comparison to LE according 
to Parks and RS.26 Overall 182 tumors (58 pT1 rectal carcinomas (G1/2) and 124 benign rectal 
tumors) were identified. Both local techniques proved to be faster in comparison to RS, result-
ing in less blood loss and shorter time of hospitalization. Also, complication rates after TEM 
and LE according to Parks were significantly lower compared to RS. An important outcome in 
this study was a significant higher rate of irradical excisions after LE according to Parks (TEM 
R1=19%, Rx=5%; Parks R1=37%, Rx=16%; p = 0.001). Local recurrence rates after RS were only 
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3.7%, which was no different after TEM (8.9%). Following LE according to Parks local recurrence 
rate was 26.3% (p = 0.0055 versus TEM). Statistical analysis of risk factors for development of a 
recurrence, detected only tumor-size (p = 0.0236) and recurrent tumor at the time of operation 
(p = 0.0231) to be significant. Tumor grading, tumor dignity (adenoma/carcinoma), distance 
from the anal verge and residual status (R0, R1, Rx) proved to be non-significant factors. Disease 
specific survival rates between the three treatment groups were comparable.
Two retrospective studies could be identified comparing TEM to RS. Heintz et al. found in 
case of a T1 low-risk carcinoma, meaning well to moderately differentiated without lymph 
Table 2. Comparative series of TEM versus LE according to Parks and/or radical surgery.


















Retrospective pT1,G1/2 TEM 20 IIIb
Parks 20
RS 18
RCT= randomized controlled trial, cT/N= clinical T/N-staging, uT/N= presumed T/N-stage based on en-
dorectal ultrasound, pT= T-stage based on histopathological investigation, G1= well differentiated, G2= 
moderately differentiated, TEM= transanal endoscopic microsurgery, RS= radical surgery
‡= according to Oxford Centre for Evidence-based Medicine Levels of Evidence.
Table 3. Comparative series of TEM versus LE according to Parks and/or radical surgery.
























TEM low risk 46 










TEM high risk 12

































NS NS 100 (2-years)
100 (2-years)
93 (2-years)
TEM= Transanal Endoscopic Microsurgery, Parks = LE according to Parks, RS = radical surgery, R0 = micro-
scopic radical excision, LR = local recurrence, OR = overall recurrence, OS = overall survival
DFS = disease free survival, DSS = disease specific survival; survival rates are 5-years, unless otherwise speci-







vascular-invasion, TEM resulted in 78% radical excisions (R0).36 In this subgroup of 46 tumors, 
after TEM local recurrence rate was four percent compared to three percent after RS for T1 
low-risk carcinomas; this difference was not significant. Overall survival rates between both 
treatment groups were comparable (TEM 79%, RS 81%). In case of a T1 high-risk carcinoma, that 
is poorly differentiated and/or (lymph-) vessel invasion, using TEM only 58% of tumors could be 
excised radically (R0). Local recurrence rate after TEM was 33%, compare to 18% after RS. Overall 
survival rate after TEM was 62%, compared to 69% after RS.
Lee et al. compared TEM with RS for cT1N0 rectal carcinomas, well or moderately differenti-
ated.37 Local recurrence rates were comparable (TEM four percent, RS zero percent; p = 0.95). 
Also overall and disease-free survival rates were comparable.
There is an abundance of published case series reporting on outcome after TEM for T1 rectal 
carcinomas.38-53 (Table 4) Inclusion criteria in these studies are not always clear, and immediate 
salvage procedures were sometimes performed, thereby possibly introducing a selection bias. 
In all series TEM is a safe procedure with complication rates varying between 5-26 percent. 
These complications are almost always minor with re-operation rates between 0-7 percent. 
Mortality is rare after TEM. All studies have a follow-up duration of more than 24 months and 
recurrence rates vary between 0-26 percent. If calculated, five years disease specific survival 
rates after TEM vary between 81-100 percent and overall survival rates range from 73 to100 
percent.
PREOPERATIVE TUMOR SELECTION
Although TEM seems to be the method of choice in local excision of T1 rectal carcinomas, local 
recurrence rates remain high. Can results be further improved by proper tumor selection?
One of the problems encountered is the unexpected finding of a carcinoma in presumed 
adenomas. This rate can be as high as 34%. A possible solution might be identifying genomic 
events within the adenoma fraction of a carcinoma, as recently reported by Lips et al.54, 55 They 
found specific chromosomal events, gain of 8q22-24, 13q and 20q, and loss of 17p and 18q12-
22, to be far more abundant in carcinomas than in adenomas. In adenoma fractions from cases 
with a carcinoma (infiltrating at least in the submucosa), twice the amount of such ‘malignant 
aberrations’ was observed, compared to pure adenomas. Furthermore, combined aberrations 
such as gain of 13q and loss of 18q were only found in adenomatous fractions of carcinomas 
and not in benign lesions. Based on these five genomic events associated with carcinoma, a 
clear distinction between adenoma and carcinoma tissue could be made. Whether these results 
are clinically relevant, remains to be seen. It seems more relevant to identify tumors suitable for 
TEM, that is rectal adenomas and T1 rectal carcinomas, which have to be discriminated from T2 
or more invasive carcinomas, as these latter have to be treated by radical surgery. Most studies 
focusing on T-stage, found endorectal ultrasound (ERUS) to be more accurate than conventional 
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No. Comments LR OS DSS
Smith
(1996)50






G3 in selected 
patients (N=4)
64 No adjuvant therapy 2/52 (4%) NS NS
Demartines
(2001)42
prospective G1/2, LVI - 9
One pt adjuvant 
therapy, type NS
1/7 (14%) NS NS
De Graaf
(2002)41
retrospective NS 21 No adjuvant therapy 2/19 (11%) NS NS
Dafnis
(2004)40
retrospective NS 10 No adjuvant therapy 1/10 (10%) NS NS
Stipa
(2004)52
retrospective uT1-T3, < 3 cm 39
Overall 43% of pts 
pre-/postoperative RT




G1/2, < 3cm, 
<10 cm from 
dentate line, 
cN0
25 No adjuvant therapy 0/25 (0%) NS NS
Endreseth
(2005)44
retrospective NS 8 No adjuvant therapy 0/8 (0%) NS NS
Floyd
(2006)45




One pt postoperative 
CRT

















retrospective uT1/T2, uN0 23
2 pts preoperative 
CRT
2 pts postoperative RT
2/23 (9%) 91% 91%
Bretagnol
(2007)39




2 pts immediate RS
Pre-/postoperative 
CRT not clear






0/51 (0%) 94% 100%
Maslekar
(2007)48
prospective G1/2 en 3 27 No adjuvant therapy 0/27 (0%) NS NS
uT/N= presumed T/N-stage based on endorectal ultrasound, pT= T-stage based on histopathological inves-
tigation, G1= well differentiated, G2= moderately differentiated, G3= poorly differentiated, NS= not stated, 








computerized tomography (CT) scanning and magnetic resonance imaging (MRI).56 Whether 
ERUS has additional value in the preoperative staging of rectal tumors, especially in identifying 
tumors possibly suitable for TEM, should be addressed properly.
Depth of invasion is not the only criterion in identifying tumors suitable for TEM. Main differ-
ence between TEM and radical surgery is the omission of lymph node dissection. In general in 
T1 rectal carcinomas it is assumed lymph node metastases are present in 4-14% of cases.57 A 
more recent study performed by Nascimbeni et al. found invasion in submucosa level 3 (Sm3), 
lymph vessel invasion and distal rectal carcinomas to be significant contributors to lymph node 
metastases.58
Can we identify, preoperative, tumors already harboring lymph node metastasis? Using single 
nucleotide polymorphism array analysis of chromosomal instability patterns in rectal tumors, 
the finding of gain on chromosome 1q might correlate with lymph node metastasis, however 
validation studies have to be awaited. None of the conventional pre-operative staging meth-
ods, ERUS/CT-scan/MRI has yielded satisfactory results upon identifying lymph node metasta-
ses. A recent break through was the introduction of MRI-USPIO.59, 60 Preliminary data show an 
increased accuracy for nodal status prediction as compared to non-enhanced MRI. However, 
again further studies have to be awaited.
POSTOPERATIVE TUMOR SELECTION
In most cases based on definite histopathological staging after LE a decision has to be 
made upon the necessity for immediate salvage surgery. In case additional salvage surgery 
is performed after LE according to Parks, controversy remains upon outcome.61, 62 Accepted, 
although not validated, low-risk criteria in T1 rectal carcinomas, are well to moderate differ-
entiation, carcinomas smaller than three centimetres, without lymph vessel invasion. Above 
these features, probably excision margin (microscopic radical (R0) versus microscopic irradical 
(R1)) may be of major importance. Only three studies specifically addressed the outcome after 
TEM for low- versus high-risk carcinomas. Mentges et al. found recurrence rates after TEM for 
low-risk carcinomas (n= 52) to be only 3.8 percent; however recurrence rates for high risk carci-
nomas (n= four) were not given, thereby prohibiting adequate comparison.49 A retrospective, 
comparative study was performed by Heintz et al.36 In low-risk carcinomas (n=46) in 78 percent 
an R0 excision margin with TEM was obtained, whereas in high-risk carcinomas (n=12) only 58 
percent of tumors were excised microscopic radical. Regarding local recurrences, in the low-risk 
group two carcinomas recurred (four percent) and in the high-risk group four carcinomas (33 
percent). All recurrences were after a microscopic irradical (R1) excision. Overall survival rates 
after TEM for low- and high-risk carcinomas were 79 and 62 percent respectively (p-value not 
given).
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A meticulous evaluation was performed by Borschitz et al, with emphasis on margin of exci-
sion.38 In 105 tumors TEM was performed. Immediate salvage was performed in 21 tumors, 
for varying reasons. In case a R0 excision was obtained, that is an excision margin of > 1 mm, 
in low-risk carcinomas recurrence rate was only four percent. In high-risk carcinomas with R0 
status, the local recurrence rate was already 20 percent. If the excision margin was < 1 mm, 
unknown (Rx) or positive (R1), the local recurrence rate after TEM was 46 percent. Immediate 
radical surgery in case of margin < 1 mm, unknown margin status (Rx) or positive margin (R1), 
results in local recurrence rates of six percent. Survival rates in low-risk carcinomas, microscopic 
radically excised are 94 percent and if microscopic irradical excised 57 percent. Immediate radi-
cal surgery in irradical excised T1 carcinomas results in survival rates of 93 percent. 
In contrast to the above studies, Langer et al. found 24 percent of all TEM specimens to be R1 
or Rx, but excision margin status was not of significant influence on developing local recur-
rences.26 This unexpected finding was thought to be reflected by inadequate follow up and/or 
limited patient numbers. All above findings warrant a larger study, specifically addressing the 
role of histopathological staging in predicting high probability for a local recurrence after TEM 
for T1 rectal carcinomas.
SALVAGE SURGERY FOR LOCAL RECURRENCES FOLLOWING TEM
Local recurrences in rectal cancer after radical surgery (TME) are considered incurable, with 
only few patients amenable to salvage surgery. Recurrences after LE seem to be more related 
to the rectum than to the pelvic wall, as is seen in recurrences after RS. In the literature most 
series on salvage surgery for local recurrences after LE lack both an adequate number of 
patients undergoing salvage procedures and adequate follow-up to allow proper analysis. 
Disease free survival rates following salvage procedures for local recurrences after local excision 
range between 30-58 percent.63-66 Moreover, to obtain a R0 resection, extended resections are 
required, often involving multi-visceral excision. Results after salvage surgery were significantly 
worse compared to immediate radical surgery in case of adverse histopathological features.61 
One must realize however that the above series and data are based on local recurrences after 
LE according to Parks.
In T1 rectal carcinomas local recurrence rates after TEM vary between 0-26 percent. Salvage 
surgery in case of a local recurrence after TEM seems amenable to most patients, with often a 
possible R0 resection.51 However, because of the low number of patients and short duration of 








Preoperative chemoradiation in rectal carcinomas results in significant downstaging with com-
plete pathological response in approximately 15 percent of advanced rectal carcinomas.67-71 
These figures might even be improved in earlier stages of rectal cancer.72 If local control is 
improved by preoperative radiotherapy and preoperative chemoradiotherapy results in steril-
izing lymph node metastases, local excision following preoperative chemoradiotherapy might 
be a logical step. One randomized controlled trial investigating this treatment strategy was 
performed.73 Forty patients with histologic proven adenocarcinomas, staged as uT2-N0-M0, 
G1/2, within six centimeters from the anal verge, were randomized to TEM or laparoscopic 
TME. Preoperative chemoradiotherapy was given by means of 5,040 cGy in 28 fractions with 
concomitant 5-fluorouracil infusion (2000 mg/m²/day). Restaging was performed and patients 
went on to the planned operation. Surgery was not influenced by preoperative treatment. 
Local and distant recurrence rates were 10 percent following TEM and 12 percent following 
laparoscopic TME. Overall survival rates were 95 percent and 83 percent respectively. All differ-
ences were not significant. Because this study has several major methodological shortcomings, 
one has to be cautious to draw any conclusions from this single study.
Another proposed regimen is a rectal sparing treatment after neoadjuvant treatment with clini-
cal complete response.74 Definite evidence, ideally by means of a randomized controlled trial, 
has to be awaited and until then this treatment should be considered experimental.
In the near future, special focus of interest will be on non-surgical therapy or local excision 
of rectal carcinomas following neo-adjuvant chemoradiotherapy. The only series on TEM fol-
lowing neo-adjuvant chemoradiotherapy showed the procedure to be feasible with promising 
early results. Again however, before definite conclusions can be drawn, larger, randomized 
studies have to be initiated.
In conclusion, based upon merely retrospective case series, TEM has been incorporated 
enthusiastically in the surgical armamentarium. Despite the lack of level I evidence, TEM seems 
justified in well-selected T1 rectal carcinomas. To avoid unjustified use of TEM in rectal carci-
nomas, using molecular profiling, combined with improved radiological staging modalities, 
besides node positive tumors, also tumors with a high chance of a local recurrence have to be 
diagnosed preoperatively. Further area of investigation should be on neo-adjuvant therapies of 
rectal carcinomas combined with TEM in a randomized setting.
TEM for T1 rectal cancer: review 21
REFERENCES
 1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
 2. Association of Comprehensive Cancer Centres. Utrecht, The Netherlands.  [May 2009 last accessed].
 3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
 4. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK 
multicentre randomised trial. Lancet 2002; 359:1291-300.
 5. Lisfranc J. Observation on a cancerous condition of the rectum treated by excision. Dis Colon Rectum 
1983; 26:694-695.
 6. Amussat JZ. Notes on the possible establishment of an artificial anus in the lumbar region without 
entering the peritoneal cavity. Dis Colon Rectum 1983; 26:483-7.
 7. Kraske P. Zur Exstirpation Hochsitzender Mastdarmkrebse. Verh Dtsch Ges Chir 1886; 14:464-74.
 8. Miles WE. A method of performing abdomino-perineal excision for carcinoma of the rectum and 
terminal portion of the pelvic colon. Lancet 1908:1812-3.
 9. Hartmann H. Nouveau procédé d`ablation des cancers de la partie terminale du colon pelvien. Con-
gres Francais de Chirurgia 1923:2241.
 10. Dixon CF, Benson RF. Surgical removal of lesions occurring in the sigmoid and rectosigmoid. Am J 
Surg 1939; 46:12-7.
 11. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recur-
rence? Br J Surg 1982; 69:613-6.
 12. Parks AG, Stuart AE. The management of villous tumors of the large bowel. Br J Surg 1973; 60:688-95.
 13. Janssen KM, Mazee HA, Ruers TJ, Baeten CG. [Transanal resection of large sessile rectal polyps]. Ned 
Tijdschr Geneeskd 1996; 140:1646-9.
 14. Mellgren A, Sirivongs P, Rothenberger DA, Madoff RD, Garcia-Aguilar J. Is local excision adequate 
therapy for early rectal cancer? Dis Colon Rectum 2000; 43:1064-71; discussion 1071-4.
 15. Bergman L, Solhaug JH. Posterior trans-sphincteric resection for small tumors of the lower rectum. 
Acta Chir Scand 1986; 152:313-6.
 16. Christiansen J. Excision of mid-rectal lesions by the Kraske sacral approach. Br J Surg 1980; 67:651-2.
 17. Haring R, Karavias T, Konradt J. [Posterior procotorectotomy]. Chirurg 1978; 49:265-71.
 18. Madsen HH, Kronborg O. Posterior transsphincteric rectotomy. Indications and safety. Dis Colon 
Rectum 1987; 30:939-41.
 19. Schildberg FW, Wenk H. [Sphincter-preserving interventions in rectal tumors. The posterior approach 
to the rectum]. Chirurg 1986; 57:779-91.
 20. Terkivatan T, den Hoed PT, Lange JF, Jr., Koot VC, van Goch JJ, Veen HF. The place of the posterior 
surgical approach for lesions of the rectum. Dig Surg 2005; 22:86-90.
 21. Thompson BW, Tucker WE. Transsphincteric approach to lesions of the rectum. South Med J 1987; 
80:41-3.
 22. Wilson SE, Gordon HE. Excision of rectal lesions by the Kraske approach. Am J Surg 1969; 118:213-7.
 23. Buess G, Hutterer F, Theiss J, Bobel M, Isselhard W, Pichlmaier H. [A system for a transanal endoscopic 
rectum operation]. Chirurg 1984; 55:677-80.
 24. Buess G, Kipfmuller K, Ibald R, et al. Clinical results of transanal endoscopic microsurgery. Surg Endosc 
1988; 2:245-50.
 25. Doornebosch PG, Tetteroo GW, Geldof H, de Graaf EJ. [Transanal endoscopic microsurgery: a good 
choice for local resection of rectal tumors]. Ned Tijdschr Geneeskd 1998; 142:2577-81.
 26. Langer C, Liersch T, Suss M, et al. Surgical cure for early rectal carcinoma and large adenoma: transanal 
endoscopic microsurgery (using ultrasound or electrosurgery) compared to conventional local and 
radical resection. Int J Colorectal Dis 2003; 18:222-9.
 27. Middleton PF, Sutherland LM, Maddern GJ. Transanal endoscopic microsurgery: a systematic review. 
Dis Colon Rectum 2005; 48:270-84.
 28. You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer 









 30. Bader FG, Roblick UJ, Oevermann E, Bruch HP, Schwandner O. Radical surgery for early colorectal 
cancer-anachronism or oncologic necessity? Int J Colorectal Dis 2007.
 31. Nascimbeni R, Nivatvongs S, Larson DR, Burgart LJ. Long-term survival after local excision for T1 
carcinoma of the rectum. Dis Colon Rectum 2004; 47:1773-9.
 32. Bentrem DJ, Okabe S, Wong WD, et al. T1 adenocarcinoma of the rectum: transanal excision or radical 
surgery? Ann Surg 2005; 242:472-7; discussion 477-9.
 33. Endreseth BH, Myrvold HE, Romundstad P, Hestvik UE, Bjerkeset T, Wibe A. Transanal excision vs. 
major surgery for T1 rectal cancer. Dis Colon Rectum 2005; 48:1380-8.
 34. Ptok H, Marusch F, Meyer F, et al. Oncological outcome of local vs radical resection of low-risk pT1 
rectal cancer. Arch Surg 2007; 142:649-55; discussion 656.
 35. Winde G, Nottberg H, Keller R, Schmid KW, Bunte H. Surgical cure for early rectal carcinomas (T1). 
Transanal endoscopic microsurgery vs. anterior resection. Dis Colon Rectum 1996; 39:969-76.
 36. Heintz A, Morschel M, Junginger T. Comparison of results after transanal endoscopic microsurgery 
and radical resection for T1 carcinoma of the rectum. Surg Endosc 1998; 12:1145-8.
 37. Lee W, Lee D, Choi S, Chun H. Transanal endoscopic microsurgery and radical surgery for T1 and T2 
rectal cancer. Surg Endosc 2003; 17:1283-7.
 38. Borschitz T, Heintz A, Junginger T. The Influence of Histopathologic Criteria on the Long-Term 
Prognosis of Locally Excised pT1 Rectal Carcinomas: Results of Local Excision (Transanal Endoscopic 
Microsurgery) and Immediate Reoperation. Dis Colon Rectum 2006.
 39. Bretagnol F, Merrie A, George B, Warren BF, Mortensen NJ. Local excision of rectal tumors by transanal 
endoscopic microsurgery. Br J Surg 2007; 94:627-33.
 40. Dafnis G, Pahlman L, Raab Y, Gustafsson UM, Graf W. Transanal endoscopic microsurgery: clinical and 
functional results. Colorectal Dis 2004; 6:336-42.
 41. de Graaf EJ, Doornebosch PG, Stassen LP, Debets JM, Tetteroo GW, Hop WC. Transanal endoscopic 
microsurgery for rectal cancer. Eur J Cancer 2002; 38:904-10.
 42. Demartines N, von Flue MO, Harder FH. Transanal endoscopic microsurgical excision of rectal tumors: 
indications and results. World J Surg 2001; 25:870-5.
 43. Duek SD, Krausz MM, Hershko DD. Transanal endoscopic microsurgery for rectal cancer. Isr Med Assoc 
J 2005; 7:435-8.
 44. Endreseth BH, Wibe A, Svinsas M, Marvik R, Myrvold HE. Postoperative morbidity and recurrence after 
local excision of rectal adenomas and rectal cancer by transanal endoscopic microsurgery. Colorectal 
Dis 2005; 7:133-7.
 45. Floyd ND, Saclarides TJ. Transanal endoscopic microsurgical resection of pT1 rectal tumors. Dis Colon 
Rectum 2006; 49:164-8.
 46. Ganai S, Kanumuri P, Rao RS, Alexander AI. Local recurrence after transanal endoscopic microsurgery 
for rectal polyps and early cancers. Ann Surg Oncol 2006; 13:547-56.
 47. Lezoche E, Baldarelli M, De Sanctis A, Lezoche G, Guerrieri M. Early rectal cancer: definition and 
management. Dig Dis 2007; 25:76-9.
 48. Maslekar S, Pillinger SH, Monson JR. Transanal endoscopic microsurgery for carcinoma of the rectum. 
Surg Endosc 2007; 21:97-102.
 49. Mentges B, Buess G, Effinger G, Manncke K, Becker HD. Indications and results of local treatment of 
rectal cancer. Br J Surg 1997; 84:348-51.
 50. Smith LE, Ko ST, Saclarides T, Caushaj P, Orkin BA, Khanduja KS. Transanal endoscopic microsurgery. 
Initial registry results. Dis Colon Rectum 1996; 39:S79-84.
 51. Stipa F, Burza A, Lucandri G, et al. Outcomes for early rectal cancer managed with transanal endo-
scopic microsurgery: a 5-year follow-up study. Surg Endosc 2006; 20:541-5.
 52. Stipa F, Lucandri G, Ferri M, Casula G, Ziparo V. Local excision of rectal cancer with transanal endo-
scopic microsurgery (TEM). Anticancer Res 2004; 24:1167-72.
 53. Whitehouse PA, Armitage JN, Tilney HS, Simson JN. Transanal endoscopic microsurgery: local recur-
rence rate following resection of rectal cancer. Colorectal Dis 2007.
TEM for T1 rectal cancer: review 23
 54. Lips EH, Dierssen JW, van Eijk R, et al. Reliable high-throughput genotyping and loss-of-heterozy-
gosity detection in formalin-fixed, paraffin-embedded tumors using single nucleotide polymorphism 
arrays. Cancer Res 2005; 65:10188-91.
 55. Lips EH, de Graaf EJ, Tollenaar RA, et al. Single nucleotide polymorphism array analysis of chromo-
somal instability patterns discriminates rectal adenomas from carcinomas. J Pathol 2007; 212:269-77.
 56. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and 
assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. 
Radiology 2004; 232:773-83.
 57. Hermanek P, Gall FP. Early (microinvasive) colorectal carcinoma. Pathology, diagnosis, surgical treat-
ment. Int J Colorectal Dis 1986; 1:79-84.
 58. Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of 
the colon and rectum. Dis Colon Rectum 2002; 45:200-6.
 59. Koh DM, Brown G, Temple L, et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO 
versus histopathologic findings--initial observations. Radiology 2004; 231:91-9.
 60. Lahaye MJ, Engelen SM, Kessels AG, et al. USPIO-enhanced MR Imaging for Nodal Staging in Patients 
with Primary Rectal Cancer: Predictive Criteria. Radiology 2008.
 61. Baron PL, Enker WE, Zakowski MF, Urmacher C. Immediate vs. salvage resection after local treatment 
for early rectal cancer. Dis Colon Rectum 1995; 38:177-81.
 62. Hahnloser D, Wolff BG, Larson DW, Ping J, Nivatvongs S. Immediate radical resection after local exci-
sion of rectal cancer: an oncologic compromise? Dis Colon Rectum 2005; 48:429-37.
 63. Friel CM, Cromwell JW, Marra C, Madoff RD, Rothenberger DA, Garcia-Aguilar J. Salvage radical sur-
gery after failed local excision for early rectal cancer. Dis Colon Rectum 2002; 45:875-9.
 64. Madbouly KM, Remzi FH, Erkek BA, et al. Recurrence after transanal excision of T1 rectal cancer: 
should we be concerned? Dis Colon Rectum 2005; 48:711-9; discussion 719-21.
 65. Paty PB, Nash GM, Baron P, et al. Long-term results of local excision for rectal cancer. Ann Surg 2002; 
236:522-29; discussion 529-30.
 66. Weiser MR, Landmann RG, Wong WD, et al. Surgical salvage of recurrent rectal cancer after transanal 
excision. Dis Colon Rectum 2005; 48:1169-75.
 67. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of 
a randomized trial comparing preoperative short-course radiotherapy with preoperative convention-
ally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93:1215-23.
 68. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluoro-
uracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24:4620-5.
 69. Klautke G, Kuchenmeister U, Foitzik T, et al. Concurrent chemoradiation with capecitabine and weekly 
irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 2006; 
94:976-81.
 70. Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-
modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin 
Oncol 2006; 24:650-5.
 71. Rodel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for 
rectal cancer. J Clin Oncol 2007; 25:110-7.
 72. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preopera-
tive chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23:8688-96.
 73. Lezoche E, Guerrieri M, Paganini AM, et al. Transanal endoscopic versus total mesorectal laparoscopic 
resections of T2-N0 low rectal cancers after neoadjuvant treatment: a prospective randomized trial 
with a 3-years minimum follow-up period. Surg Endosc 2005; 19:751-6.
 74. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal 




Aim of the thesis

Aim of the thesis 27
AIM OF THE THESIS
Local excision, and in particular transanal endoscopic microsurgery (TEM), is increasingly being 
applied in the treatment of T1 rectal cancer. In several national guidelines this treatment option 
is incorporated, however several issues have to be addressed before this is justified.
Chapter 1 contains a review of the relevant literature on TEM for T1 rectal cancer.
The aim of the thesis, outlined here in chapter 2, is to define which T1 rectal cancers are suit-
able for TEM, in order to improve outcome. Besides oncologic outcome, quality of life (QOL) 
after TEM is studied and compared to after TME. Also, possible improvements regarding tumor 
selection are explored.
In chapter 3 oncologic outcome after TEM for T1 rectal cancer is studied and directly compared 
to after TME.
Chapter 4 studies the possible salvage options and outcome in recurrent tumors following TEM 
for T1 rectal cancer.
Chapter 5 is a study on QOL following TEM and in chapter 6 QOL after TEM is compared to QOL 
after TME.
In chapter 7 we investigated whether endorectal ultrasound could identify tumors possibly 
suitable for TEM.
In chapter 8 we performed a study upon tumor analysis in order to identify features suggestive 
of rectal cancer in (presumed) rectal adenomas.
Chapter 9 contains an analysis of histopathological features, which may be predictive for a local 
recurrence in T1 rectal cancer, treated solely with TEM.
Chapter 10 contains a summary, which is also given in Dutch in chapter 11.

CHAPTER 3
Transanal endoscopic microsurgery versus 
total mesorectal excision of T1 rectal 
adenocarcinomas with curative intention
E.J.R. de Graaf, P.G. Doornebosch, R.A.E.M. Tollenaar, E. Meershoek-Klein 
Kranenbarg, A.C. de Boer, F.C. Bekkering, C.J. van de Velde
Eur J Surg Oncol. 2009 Dec;35(12):1280-1285
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INTRODUCTION
In rectal cancer, total mesorectal excision (TME) is the gold standard. This optimised and 
standardized surgical technique, combined with preoperative radiotherapy, has improved out-
come. 1, 2 Counterbalancing this improvement is the high rate of (severe) morbidity and even 
mortality. 3-6 Local excision of rectal adenocarcinomas is a much safer procedure and transanal 
excision (TE) is the technique most commonly used. However, transanal endoscopic microsur-
gery (TEM) is nowadays considered the method of choice. 7 Only in T1 rectal adenocarcinomas 
TEM is considered adequate if curation is intended. 
Quirke showed that standardized processing of resection specimens for rectal adenocarcino-
mas revealed a higher percentage of incomplete excision, which significantly correlated to an 
increased risk on both local and distant recurrences and on decreased survival. 8  This resulted in 
the concept of TME and adjustment of histological examination of the specimen. Although TEM 
is being implemented in several national guidelines for T1 rectal adenocarcinomas, the role 
of pathological assessment of the specimen has been limited mainly to basic histopathologic 
criteria. 9 Excision margin status after both TE and TEM, has been demonstrated to be a predic-
tor for local recurrence, however, this has only been shown in case studies. 10-12 Most studies 
comparing outcome after local excision for T1 rectal adenocarcinomas with TME do not focus 
on excision margin status. Moreover, standardized pathological assessment lacks, and this may 
have caused the varying outcome. 13-18
As the incidence of T1 and T2 rectal cancer will most likely increase in the near future, because 
of introduction of population-based screening programs, this warrants a thorough analysis of 
oncologic outcome following TEM for T1 rectal adenocarcinomas. 19 The aim of this prospective 
study was to compare the impact of margin status, assessed with standardized pathology after 
TEM and TME for T1 rectal cancer.
PATIENTS AND METHODS
The Dutch TME trial started in 1996, and 1530 Dutch patients with mobile rectal adenocarci-
nomas were randomly assigned either to short term preoperative radiotherapy followed by 
TME or to TME alone. The study protocol included standardized processing of the specimen, 
described in detail elsewhere. 20 Only T1 rectal adenocarcinomas were considered eligible for 
this study. In the IJsselland hospital, a tertiary referral centre for TEM and participating in the 
Dutch TME trial, patients with T1 rectal adenocarcinomas were also deemed feasible for TEM. 
Selection was based upon the same study protocol, with complementary rigid rectoscopy and 
endorectal ultrasound (ERUS). Eligibility for the current study was in accordance with the Dutch 
TME trial protocol with some exceptions. Patients who underwent TME and had synchronous 







been therapy of choice, metastases would not have been disclosed. Furthermore, patients who 
previously underwent pelvic operations or resections of left-sided large bowel or rectum were 
not excluded. For TEM patients World Health Organisation Performance Score (WPS) was not a 
criterion (in the Dutch TME trial WPS limited to 2 or less was an inclusion criterion). TEM patients 
were only eligible if there were no signs of lymph node metastases on MRI and/or ERUS and 
excision margins were negative.
If T1 rectal cancer only emerged at histology of the excised specimen following TEM, patients 
were offered follow-up only or immediate additional TME. In case excision margins were 
positive following TEM, patients also were offered immediate TME or intensive follow up after 
repeat TEM, in order to obtain negative excision margins. The TEM technique is described in 
detail elsewhere. 21 Tumor size after TEM as well as TME was assigned as the largest diameter. 
TEM specimens were pinned on a corkboard before fixation. Fixation, serial transverse slicing, 
embedding, staining, sectioning and examination of the specimens were done according to 
descriptions detailed elsewhere. 8, 20 
Both groups were followed according to the Dutch TME trial protocol. Moreover, rigid rectoscopy 
and endorectal ultrasound were performed at every visit except for the colonoscopy visit in 
the TEM patients. Endpoints studied were morbidity, mortality, margin status, local recurrence, 
distant recurrence, overall survival and cancer specific survival. Local recurrence was defined 
as evidence of a tumor within the lesser pelvis. Distant recurrence was defined as evidence of a 
tumor in any other area. In all patients in this study informed consent had been obtained.
Data were analyzed with SPSS statistical software (version 14.0 for Windows, SPSS, Chicago). 
Chi-square tests were used to compare proportions. Mann-Whitney tests were used to compare 
continue variables. Univariate analyses of cumulative probability of local and distal recurrence, 
as well as overall and cancer-specific survival were carried out by the Kaplan-Meier method, 
and the evaluation of differences between the two groups was performed with the log-rank 
test. The Cox proportional hazards model was used to calculate hazard ratios and 95% confi-
dence intervals in the univariate and multivariate analyses. A two-sided p-value of 0.05 or less 
indicated statistical significance.
RESULTS
Of the 1530 Dutch patients entered in the TME trial, a total of 76 patients with T1 rectal adeno-
carcinomas were present (5%). One patient was excluded because of a second malignancy. 
Seventy-five patients were eligible for this study. In 1 patient excision margin was positive 
(1.3%). In 86 patients TEM was performed for T1 rectal adenocarcinomas. In 5 patients excision 
margins were positive (5.8%). Six patients, including 2 patients with incomplete margins, chose 
for additional TME and were excluded. Eighty patients were entered in the study, including the 
remaining 3 patients with initial positive excision margins. TEM was repeated in these patients, 
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no residual tumor tissue was found and excision margin was considered negative. Patient, 
tumor and operation characteristics are depicted in Table 1. Both groups were comparable, 
except that TEM patients had higher WPS pre-operatively (p < 0.001). 
TEM proved to be safer compared to TME reflected by operating time, blood loss, hospital stay, 
morbidity, re-operations and stoma formation (all p < 0.001). Complications after TEM were 
present in 5 patients (5.8%). In three patients a urinary tract infection occurred, and one patient 
with a cardiac history suffered from cardiac pain and dysrythmia leading to medical treatment 
on the coronary care unit. In one patient, following a segmental resection, anastomotic stenosis 
with disabling complaints occurred. Hegar dilation proved unsuccesful, necessitating renewed 
TEM for correction. Histopathologic evaluation only showed fibrosis. After TME, 48 patients 
suffered from 72 complications (64%). The majority was severe, necessitating re-operations in 
13.3% of all patients (anastomotic leakage 6.9%, re-bleeding 9.3% and ileus 6.7%). In 58 patients 
a primary anastomosis was constructed, with a diverting ileostomy in 44. In two patients a Hart-
mann’s procedure was performed and in 15 patients an abdomino-perineal excision. A stoma 
was constructed during re-operation in another 2 patients. Ten out of 44 diverting ileostomies 
have never been reversed and in 5 patients after reversal again a stoma was constructed result-
ing in 43% of the TME patients having a definite stoma at the time of evaluation. Following TEM, 
five (6%) patients had a colostomy, because of a local recurrence necessitating salvage surgery. 
(Table 2) There was no mortality after TEM, and after TME 4% of patients died (p = 0.07). Median 
follow-up after TEM was 42 months (range, 1-127) and after TME 84 months (range, 30-115). 
Local recurrence rate was 24% after TEM compared to 0% after TME patients (p < 0.0001; Figure 
1). Details of local and distant recurrences following TEM and TME are given in Table 2. After 
TEM 15 local recurrences were observed of which 13 were diagnosed within the first 18 months 
(86.7%). Median time to local recurrence was 10 months (range, 5-50). In 12 patients (80%) 
salvage surgery was performed, limited to TME, without mortality and without renewed local 
recurrences.
Distant metastases developed in 6 patients. None of the TEM patients without local recurrence 
developed distant metastases or died cancer-related. After TME 6 patients developed distant 
recurrences. Overall survival was 75% after TEM and 77% after TME (p = 0.9; Figure 2). Cancer 
specific survival was 90% after TEM and 87% after TME (p = 0.5; Figure 3). In regard to both 
overall survival and cancer-specific survival, neither surgical technique used, age, gender or 
WPS were risk factors.
DISCUSSION
After TME for rectal adenocarcinomas, morbidity varies from 10 to 62%, and mortality var-
ies from 3.3 to 25.8%. 1-6 Morbidity is often severe, especially if preoperative radiotherapy is 







morbidity and mortality is often the motive for local excision in rectal adenocarcinomas. Mor-
bidity is predominantly minor, occasionally leading to re-operation and formation of a stoma 
and without functional disorders having impact on quality of life. 22 Morbidity and mortality in 
Table 1. Patient-, tumor- and operation characteristics of the patients enrolled in the study.
TEM TME
Number of patients 80 75
Age (yrs) 71 (44-92) 67 (48-83) ns
Female: male 32: 48 27: 48 ns
WPS 0: 1: 2/3 42: 18: 20 60: 14: 0 p < 0.001
Tumor diameter (cm) 3.0 (0.5-13) 2.5 (0.5-7.5) ns













Operating time (min) 40 (10-125) 180 (70-360) p < 0.001
Blood loss (ml) 0 (0-250) 1000 (50-15000) p < 0.001






































































All p < 0.001











Mortality (%) 0 3 (4.0) P = 0.07
WPS = World Health Organization Performance Score; data given are numbers or medians with ranges 
between parentheses. Morbidity = number of patients with one or more complications.
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this study are in line with literature and again demonstrate the safety of TEM and the conse-
quences of TME. This is even reinforced by the fact TEM patients had worse WPS compared to 
TME patients.
However, morbidity should not be the main endpoint measured when choosing between two 
operation techniques for rectal adenocarcinomas. After local excision of rectal adenocarcino-
mas, outcome varies strikingly, even when limited to T1 rectal adenocarcinomas. As a result, it 
is looked at with caution and most authors emphasize its adoption only in carefully selected 
patients. 23
Microscopic radical excision is a prerequisite to diminish recurrences after TME for rectal cancer. 
8 Standardized histological examination revealed a higher percentage of incomplete resection 
with significant correlation to an increased risk on both local and distant recurrences and on 
decreased survival. This resulted in the concept of TME and adjustment of histological examina-
tion of the TME specimen. Excision margin status after local excision is also a significant prog-
nostic factor. In 1990 Graham concluded that after local excision positive excision margins were 





















TEM Yes 5 LAR pT3N0 R0 - - 16 Alive
TEM Yes 5 APR pT2N0 R0 - - 34 DNCR
TEM Yes 6 APR pT2N0 R0 - - 33 DNCR
TEM Yes 7 LAR pT2N0 R0 - - 69 Alive
TEM Yes 10 APR pT3N0 R0 - - 69 Alive
TEM Yes 10 LAR pT3N0 R0 - - 16 Alive
TEM Yes 11 LAR pT3N1 R0 - - 19 Alive
TEM Yes 12 LAR pT3N0 R0 - - 20 Alive
TEM Yes 40 CTh,APR pT0N0 R0 - - 49 Alive
TEM Yes 5 LAR pT3N0 R0 Liver,lung 5 13 DCR
TEM Yes 12 LAR, CTh pT3N2 R1 Liver 27 39 DCR
TEM Yes 19 Hp pT2N0 R0 Liver 19 40 DCR
TEM Yes 5 None cT3 - Liver 5 15 DCR
TEM Yes 20 CTh cT4 - Liver 22 30 DCR
TEM Yes 50 CTh cT4 - Lung 50 52 Alive
TME No - - - - Skin 5 7 DCR
TME No - - - - Peritoneal 0 20 DCR
TME No - - - - Liver, bone 28 29 DCR




TME No - - - - Liver 23 39 DCR
TME No - - - - Lung 16 57 DCR
APR= abdomino-perineal resection; AR= anterior resection; Cth= chemotherapy; Hp= Hartmann’s proce-
dure; - = not applicable; p= pathological; c= clinical; R0= microscopic radical; R1= microscopic irradical; 
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associated with increased local recurrence rates and decreased survival. 11 Also in case studies 
on TEM, excision margin status has proven to be a predictor for recurrence. 10, 12 However, 
comparative studies, focusing on TE or TEM and TME for T1 rectal adenocarcinomas, are subject 
to possible bias as patient selection criteria and (neo-) adjuvant strategies are not elucidated. 
Furthermore, the method of histological investigation remains unclear and the presence of 
incomplete or doubtful margins was not an exclusion criterion. 
Unprotocollized histopathologic evaluation leads to underestimation of positive excision 
margins. 12, 24 With TEM, even with standardized histopathologic evaluation, negative excision 
margins can be obtained in over 90% of specimens. 25 This may be one of the most contributing 
factors to improved oncologic outcome following TEM, compared to after TE. 16 This hypothesis 
warranted the current study.
Regarding survival, we found that if negative excision margins are confirmed by thorough, 
protocollized histopathologic evaluation, no differences between TEM or TME occurred. This 
is in line with all other comparative studies of TEM and TME. 16-18 Following TME never a local 
recurrence occurred, and after TEM, despite a 100% negative excision margin status, local recur-
rence rate was 24%. This is higher than the 4.1 to 10% observed by other TEM centres and even 
higher to the 4 to 18% after TE. A possible explanation for this result has yet to be clarified.
Focussing on prevention of local recurrence after local excision of rectal cancer is caused by the 
fact that local recurrences after radical excision are difficult to treat with many renewed local 
recurrences and poor prognosis. 26 Literature on salvage surgery for local recurrence after local 
excision is limited. Most series lack both an adequate number of patients undergoing salvage 
procedures and adequate follow-up to allow proper analysis. It only concerns local recurrences 
following TE as technique used. 27, 28 Disease free survival rates following salvage procedures 
range between 30-58%. Moreover, to obtain a R0 resection, extended resections are required, 
often involving multivisceral excision. Results after salvage surgery are worse compared to after 
immediate salvage surgery in case of adverse histopathologic features. 10, 24, 29 Salvage surgery 
in case of a local recurrence following TEM seems amenable to most patients, with often a pos-
sible R0 resection.  In this study, of 15 local recurrences 12 were amenable to salvage surgery 
(80%), of which in 11 (92%) a R0 resection could be obtained by performing a TME. Maybe 
the elegant and precise technique of TEM is the key element for these results. Or perhaps it 
was the early detection due to the intensive follow-up. About 90 per cent of recurrences were 
diagnosed within 18 months. Moreover, about 25% of the local recurrences were diagnosed 
only with endorectal ultrasound as described by others. 30
In conclusion, TEM is a safer procedure than TME for T1 rectal adenocarcinomas. Despite obtain-
ing a negative excision margin status, local recurrence rate is still unacceptably high and efforts 
should be made to investigate prognostic factors. Survival rates are comparable after TEM and 
TME, although long-term results have to be awaited. Salvage surgery for local recurrences is 
possible, however future studies are needed to spare as many patients as possible from the 
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INTRODUCTION
Total mesorectal excision (TME) is the gold standard for rectal cancer, because this treatment 
modality offers the highest chance of cure. This standardised and optimised surgical technique 
has lowered the recurrence rates and improved survival.1,2 In an attempt to avoid the substan-
tial morbidity and mortality of TME, local excision has been suggested a therapeutic option in 
the treatment of well-selected patients with early rectal cancer.3,4 But, after transanal excision 
unacceptable high rates of incomplete tumor removal in up to 39 percent have been observed, 
proven to be a key predictor for recurrence.5-9
Transanal endoscopic microsurgery (TEM), introduced by Buess et al.10, is an optimised tech-
nique for the local excision of rectal tumors, which enables excellent access and visualization of 
the surgical field and allows precise and full-thickness excision of the tumor. Using TEM, the rate 
of microscopic negative excision margins (R0), even with standardised pathology, for T1 tumors 
exceeds 90%.11,12 Because of this latter, in combination with the very low mortality and morbid-
ity rates, TEM is nowadays considered a potential curative treatment of T1 rectal cancer.5,13,14 
However, even after TEM local recurrence rates range from 0 to 24%, and the results of salvage 
surgery for recurrent tumors are matters of concern. 15-17 In literature, only salvage surgery 
after transanal excision of T1 rectal cancer is addressed. 18-20 To our knowledge no data exist on 
patients treated for a recurrence after TEM surgery and in this study we present the treatment 
possibilities and outcome of patients with a local recurrence after TEM for T1 rectal cancer.
PATIENTS AND METHODS
From 1996, in the IJsselland hospital, a referral centre for TEM, 88 consecutive patients under-
went TEM for pT1 rectal cancer and were followed as part of a prospective, comparative study. 
As described previously all patients were screened according to a standard protocol.21 The 
initial TEM procedure was performed by two surgeons. A full-thickness excision was performed 
in all lesions, and in all tumors a microscopic negative excision margin of 2 millimetres or more 
was obtained (R0), as shown by protocollized pathology. None of the patients received any 
form of (neo-) adjuvant treatment. Follow-up was according to the Dutch guidelines on rectal 
cancer with additional rigid rectoscopy and endorectal ultrasound (ERUS) every 3 months the 
first 2 years, and every 6 months thereafter for the detection of local recurrences. During the 
last two years of the study period magnetic resonance imaging (MRI) of the lesser pelvis was 
introduced as a part of the follow-up as well, and nowadays is routinely performed at 12, 24 and 
36 months. A local recurrence was defined as recurrent tumorous tissue within the lesser pelvis 
and endoluminal, if present, within the proximity of the scar tissue of the initial operation. All 
recurrences were histologically proven and when appropriate, salvage surgery was performed. 







preoperative short-course radiotherapy (six patients) and nowadays with preoperative long-
course chemoradiotherapy (five patients).
Following salvage surgery, patients were followed according to the Dutch guidelines for rectal 
cancer. Patient data were collected in a central, digital database. Patient survival was assessed 
using the Kaplan–Meier life-table method. 
RESULTS
Out of 88 patients followed, in 18 patients a local recurrence occurred. Patient and primary 
tumor characteristics are depicted in Table 1 and 2. Only three tumors primarily harboured 
accepted high-risk features, which are poor differentiation and/or (lymph-) vessel invasion. All 
others were so-called low-risk tumors. Besides these features, of 16 tumors with known submu-
cosal invasion depth, six invaded the deep part of the submucosa (Sm3). 
Median age of patients at the time of recurrence was 74 years (range, 56-84), 50% of the 
patients were male. Median time to a local recurrence after the initial TEM procedure was 10 
months (range, 4-50). At regular follow-up visits, ten recurrences were found intra-luminal and 
six patients extra-luminal, only visible with ERUS. In two patients recurrences were detected 
only with MRI. The first patient (patient number 13) refused intensive follow-up, and presented 
one year later with lower back pain. MRI showed a locally advanced (cT4) recurrence. The 





Interval between TEM and 
local recurrence (months)
1 74 female 2 10
2 83 female 3 6
3 79 male 3 19
4 82 male 3 5
5 77 female 3 7
6 72 female 1 20
7 68 male 3 5
8 61 male 3 12
9 84 female 2 11
10 56 male 1 6
11 80 male 2 11
12 71 female 1 12
13 75 male 3 41
14 72 female 1 10
15 64 male 1 50
16 80 female 1 24
17 73 female 2 4
18 59 male 1 7
ASA= American Society of Anaesthesiologists.
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second patients (patients number 15) had complaints in between two (intensive) follow-up 
visits and MRI showed as well a locally advanced local recurrence pre-sacral. MRI was not part 
of the intensive follow-up protocol at that time. Most probably the recurrence was missed at 
rectoscopy and ERUS. Following neo-adjuvant chemoradiotherapy a microscopic negative 
excision margin was obtained in both.
Salvage surgery characteristics are given in Table 3.Two patients were not operated. Patient 
number 6 withdrew from intensive follow-up and presented elsewhere with low back pain 20 
months after the TEM procedure. A clinical T4 local recurrence was found with synchronous 
metastatic disease in the liver. Palliative chemotherapy was started, and the patient died ten 
months later.
In patient number 9, preoperative work-up failed to diagnose a T1 rectal cancer. For unclear 
reasons, postoperative additional investigations, focusing on metastatic disease, were not per-
formed. Six months after the TEM procedure already a local recurrence was suspected, which 
could only be confirmed half a year later, after repeated biopsies. At the time of diagnosis, 
massive hepatic metastases causing liver failure were found and she died three months later.
Salvage surgery was performed in 16 patients. In two patients (patient number 3 and 7) 
synchronous liver metastases, initially deemed resectable, were found. Despite obtaining a 
Table 2. Initial tumor characteristics at TEM operation.





Differentiation grade LVI BVI Sm classification
1 52.00 0.3 Moderate No No Superficial
2 7.50 6 Moderate No No Deep
3 36.00 17 Moderate No Yes Superficial
4 56.25 1.8 Moderate No No Deep
5 2.25 8 Good No No Deep
6 12.00 5 Moderate No No Superficial
7 14.00 17 Moderate No Yes Superficial
8 49.00 6 Poor Yes Yes Superficial
9 63.00 5 Moderate No No Superficial
10 49.00 15 Moderate No No Deep
11 42.00 10 Moderate No No Superficial
12 7.50 6 Moderate No No Deep
13 17.50 10 Moderate No No Deep
14 52.00 15 Moderate No No Superficial
15 10.00 10 Moderate No No Superficial
16 3.00 10 Moderate No No Superficial
17 5.00 16 Moderate No No Unknown
18 27.50 5 Moderate No No Unknown








microscopic negative excision margin in both, rapidly progressive metastatic disease devel-
oped and patients were treated with palliative chemotherapy. They died seven and respectively 
22 months following the salvage procedure.
In 15 out of 16 salvage procedures, a microscopic negative excision margin was obtained, with-
out the need for multivisceral resections. In one patient a microscopic positive excision margin 
(R1) was obtained, and adjuvant chemotherapy was administered. There was no postoperative 
mortality. Median follow up after salvage treatment was 20 months (range, 2 – 112). One of the 
operated patients developed a local re-recurrence and 7 patients developed distant metastases 
and died because of progressive disease. 
The overall survival after salvage surgery at 1 year was 79% and at 3 years only 31%. (Figure 1) 
Since there were two non-cancer related deaths (patient 2 and 4) the cancer related survival at 
one year was 79% and at 3 years 58%. (Figure 2)














1 APR none pT3N0M0 R0 - - 112 Alive
2 APR none pT2N1M0 R0 - - 32 DNCR
3 HP 5x5 pT3N2M1 R0 Liver - 22 DCR
4 APR none pT2N0M0 R0 - - 28 DNCR
5 LAR 5x5 pT3N0M0 R0 - - 92 Alive
6 None none cT4NxM1 - Liver Palliative 
ChT
10 DCR
7 APR 5x5 pT3N0M1 R0 Liver, lung - 7 DCR
8 LAR 5x5 pT3N2M0 R1 Liver ChT 13 DCR
9 None none cT3NxM1 - Liver Palliative 
ChT
3 DCR
10 LAR 5x5 pT3N0M0 R0 - - 31 Alive
11 LAR 5x5 pT3N1M0 R0 Lung, re-LR - 27 DCR
12 LAR none pT3N0M0 R0 - - 25 Alive
13 APR CRT pT0N0M0 R0 - - 27 Alive
14 LAR none pT3N0M0 R0 - - 20 Alive
15 APR CRT pT3N0M0 R0 - - 18 Alive
16 LAR CRT pT3N2M0 R0 Liver - 8 DCR
17 LAR CRT pTisN1M0 R0 - - 6 Alive
18 LAR CRT pT0N1M0 R0 - - 2 Alive
APR= abdomino-perineal resection; LAR= low anterior resection; HP= Hartmann’s procedure; TNM= tumor 
node metastasis classifi cation; R0= microscopic negative excision margin, R1= microscopic positive exci-
sion margin; DM= distant metastasis; FU= follow-up; 5x5= short-course radiotherapy, 5 times 5 Gray; CRT= 
chemoradiotherapy; ChT= chemotherapy; DNCR= died non-cancer related; DCR= died cancer related; re-
LR= renewed local recurrence.
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Figure 1. Overall survival following salvage operation.








Transanal endoscopic microsurgery (TEM) is the method of choice in the treatment of rectal 
adenomas. Morbidity as well as mortality is extremely low compared to total mesorectal exci-
sion (TME). 21 However, when considering local excision a curative option in rectal cancer for 
fit patients, surgeons face a dilemma. Although, a large majority (70-85%) of patients can be 
cured by TEM, the risk of cancer recurrence is substantially high, varying between 10% and 28% 
for pT1 rectal cancer.2,22-24 Low recurrence rates of only 0.4 to 1.7% are reported after TME.2,25,26 
In most studies reporting on local recurrences following local excision for T1 rectal cancers, 
there is a bias in patient and tumor selection. This is a major confounding factor when inter-
preting outcome. In the present series, all T1 rectal cancers excised with TEM were included, 
provided a microscopic negative excision margin (R0) was confirmed at pathological examina-
tion. In our series obtaining a R0 excision did not prevent from a local recurrence. Therefore, 
improving tumor selection is of major importance. Whether basic histopathologic criteria, 
differentiating high- and low-risk T1 rectal cancers, are able to perform this, is subject of debate. 
27-30 In our series only three T1 cancers initially exhibited so-called high-risk features (poor 
differentiation and/or (lymph-)vascular invasion). Furthermore, five tumors deeply invaded 
the submucosa (Sm3), which may also be a predictive feature for lymph node metastasis. In 
those nine presumed high-risk tumors, always salvage surgery was possible with only in one 
a microscopic positive excision margin (patient 8), whereas in nine primarily low-risk tumors 
in seven a salvage procedure was performed. The fifty percent rate of high-risk tumors seems 
high, however when reviewing our TEM specimens, of all T1 rectal cancers treated solely with 
TEM that did not recur, also 50 percent of tumors exhibited one or more of the accepted high-
risk features. Because of the low number of patients, conclusions regarding high-risk features 
and the biological behaviour of those tumors are inappropriate. Larger studies focusing on 
adequate tumor selection are therefore urgently needed.
Local recurrences may present as an intra-luminal or extra-luminal rectal mass. Therefore, next 
to rectoscopy, additional diagnostic tools seem mandatory in the follow-up regimen in patients 
treated with TEM for T1 rectal cancer. In our series, six out of 18 local recurrences were solely 
found with ERUS, which otherwise may have been missed. This finding is confirmed by other 
series focusing on the role of ERUS in the follow-up regimen of locally excised rectal cancers.31 
However, ERUS still has its limitations. In one of the two patients with a late recurrence in our 
series, one was missed with rectoscopy and ERUS. Therefore, since then MRI of the lesser pelvis 
is added as well in the follow-up protocol in our hospital. By applying this intensive follow-up 
regimen in our patients, only one out of 16 patients who adhered to this protocol, was diag-
nosed at an advanced, incurable stage. In the remaining patients, almost always a R0 resection 
was possible (94% R0).
This is the first series, to our knowledge, reporting on outcome of local recurrent disease follow-
ing TEM for T1 rectal cancer. However, comparison of the results of salvage surgery after TEM 
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and transanal excision is extremely difficult. For instance, in the studies by Friel et al. and Weiser 
et al, both T1 and T2 rectal cancers were initially included, whereas in the present series only T1 
rectal cancers were deemed feasible for TEM.27, 28 In the study from Minnesota salvage surgery 
was considered curative in 79 percent of cases. With a mean follow-up of 39 months disease 
free survival rate was 59%, with 17 percent renewed local recurrences. In the study reported 
by the group of MSKCC in 98 percent of patients a potential curative resection was possible, 
however in 55 percent of procedures a multivisceral resection was necessary. Five-year disease 
specific survival in this series was 53 percent. In our series of 16 salvage procedures, in 15 it 
was potentially curative (94 percent), and never a multivisceral resection was necessary. With a 
median follow-up of 20 months following salvage surgery, only one renewed local recurrence 
occurred. Overall survival at three years was only 31 percent and disease specific survival 58 
percent. These results do not seem better to those after failed transanal excision, however in 
the present series also two patients with incurable disease at the time of diagnosis are included, 
whereas in the other series only results after salvage procedures are given and they may have 
excluded patients with incurable disease, which may worsen results. Therefore, a clear compari-
son between outcome after failed TEM and transanal excision for T1 rectal cancer is impossible.
Obtaining a microscopic negative excision margin is a prerequisite, however does not seem to 
be the main problem in the present series. The substantial proportion of patients (39%) that 
eventually was diagnosed with metastatic disease after the salvage operation is striking. Of 
the original 88 patients never metastatic disease occurred in the absence of a local recurrence. 
An explanation could be that local recurrences after TEM for T1 rectal cancer represent a differ-
ent biological group, in which salvage treatment should be intensified. Besides neo-adjuvant 
treatment, adding adjuvant treatment in patients with a local recurrent tumour might improve 
outcome. 
In conclusion, recurrent disease after TEM for T1 rectal cancer is a major problem. Salvage 
surgery for achieving local control is feasible in most of the patients, without the need for 
multivisceral resections. This may be attributable to intensive follow-up. However, survival is 
limited, mainly due to distant metastases. Tailoring selection of T1 rectal cancers and exploring 
possible adjuvant treatment strategies following salvage procedures should be the next steps, 
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INTRODUCTION
Local excision of benign rectal tumors is safer compared to radical surgery and considered 
treatment of choice. 1-3 Several techniques have been developed for local excision, with the 
transanal technique according to Parks as the most frequently used. 1, 4 Other techniques 
used are the dorsal trans-sacral approach (Kraske) and the dorsal trans-sphincteric approach 
(York-Mason). 5-9 Each procedure has its own (dis-) advantages, and none of the procedures 
mentioned is able to achieve local excision of tumors throughout the entire rectum. Transanal 
endoscopic microsurgery (TEM) demonstrated to be a safe procedure capable of overcoming 
this shortcoming. In early publications even distal sigmoid tumors could be locally excised with 
excellent results. Moreover, recurrence rates are minimal compared to other local techniques. 
As a result the indication for local excision of rectal tumors has expanded dramatically. 10-13
Few studies have addressed functional outcome following TEM, and with the operation rec-
toscope with a length of 12 or 20 centimetres and a diameter of 40 mm, scepticism towards 
postoperative faecal continence remains. In manometric studies after TEM there seems to be 
a temporary detrimental impact on internal sphincter functioning, although without clinical 
significance. 14-16
Cataldo et al. recently performed a prospective study on faecal continence and incontinence-
specific quality of life after TEM, using standardized surveys. 17 They stated TEM does not result 
in significant alterations. These results are promising, especially with a relative short duration 
of follow-up of six weeks in this study. As known from other types of rectal surgery, incidence 
of faecal incontinence diminishes with time. 18 This could imply results after TEM may even 
improve with longer follow-up.
Quality of life is increasingly recognised as the ultimate endpoint when assessing clinical out-
comes after different surgical interventions because it measures the patient’s perspective. The 
precise impact of the TEM procedure on quality of life has not been well studied. This prospec-
tive study was set out to provide a comprehensive insight into the impact of TEM on functional 
outcome and quality of life.
PATIENTS AND METHODS
Between January 2004 and January 2006, a consecutive series of fifty patients were referred for 
a TEM procedure. All patients were evaluated preoperatively according to a standard protocol 
including rigid rectoscopy, tumor biopsy and endorectal ultrasound. If TEM was considered 
feasible patients were eligible for this study. Informed consent had to be given before inclusion. 
Local medical ethical committees approved this study. Always a full-thickness excision was per-
formed. The portion of the tumor located within the sphincter musculature was excised partial 







a questionnaire to assess anorectal functioning and quality of life. All data were collected by an 
independent research coordinator, not previously involved in the patients’ care. We recorded 
the demographics, operative details, postoperative length of stay, postoperative complications 
and functional outcome for each participant. We evaluated functional outcome by means of a 
detailed questionnaire based on the Faecal Incontinence Severity Index (FISI) 19. This system, 
developed by Rockwood, uses two basic components: the type of incontinence and its fre-
quency. FISI scores range from zero (total continence) to 61 (complete incontinence to solid 
stool on a daily basis). We used the validated weighting scores that are based on patients input.
Quality of life was evaluated using both the EuroQol EQ-5D and the Faecal Incontinence Quality 
of Life (FIQL) score. The EuroQol EQ-5D consists of a so-called Index score representing the soci-
etal value of the health state, and has a scale ranging from 0 (no quality of life) to 100 (optimal 
quality of life). The EuroQol EQ-5D also uses a visual analogue scale, the EQ-VAS, representing 
the patient perspective. This scale ranges from 0 (no quality of life) to 100 (optimal quality of 
life). The EuroQoL EQ-5D scores were compared with a sex- and age-matched, community based 
sample of healthy persons without co-morbidity.20 The FIQL score as described by Rockwood et 
al. measures specific quality of life issues, expected to affect patients with faecal incontinence. 
21 This instrument is composed of 29 questions within 4 domains: lifestyle issues, coping/behav-
ior, depression and self-perception, and embarrassment. The scores in the FIQL range from a 
minimum score of 1 to a maximum of 4, for all of the scales (1= quality of life alteration present 
most of the time, 4= none of the time). Data are presented as medians and standard devia-
tions. Changes within groups were evaluated using the nonparametric one-sample Wilcoxon’s 
signed-rank test. Comparison of these changes between groups was conducted using the 
Mann-Witney U test. The Spearman`s correlation coefficient was used for correlation between 
the different findings. A p-value ≤ 0.05 was considered statistically significant.
RESULTS
Fifty patients were eligible and informed consent was obtained. Three patients were excluded. 
In two patients TEM could not be performed because of bulky tumor or technical problems. 
An additional patient underwent low anterior resection for locally recurrent disease within six 
months of the TEM. The remaining forty-seven patients completed both questionnaires and were 
included for analysis. All of these patients were alive without evidence of recurrent disease. The 
group consisted of 22 males and 25 females. Median age was 67 years (range 40-84). Preoperative 
diagnosis was villous adenoma in all patients. Median distance from the distal tumor margin to 
the dentate line was 7 (range 0–15) cm and median tumor size 20 (range 4–53) cm2. The median 
rate of captured circumference of the rectal wall was 40 percent (range 5-80). (Table 1) Median 
operative time, defined as beginning when the rectoscope was inserted and ending when it 
was removed, was 55 minutes (range 10–140). Complications developed in 4 of 47 (8.5 percent) 
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patients. Two patients had urinary retention, one patient a urinary tract infection and one suf-
fered from a low hemoglobin rate requiring blood transfusion. No reoperations were necessary 
and mortality rate was zero. Median length of stay was 4 days (range 3-9). (Table 1)  
Definite histopathological examination of the resected specimens revealed an adenoma in 44 
patients and an invasive carcinoma in 3 patients (pT1 in two patients and pT2 in one patient). 
These three patients were reluctant to major surgery and were observed with rectoscopy and 
endorectal ultrasound every three months without signs of recurrence at six months after TEM. 
In three adenomas excisional margin was considered microscopic irradical, resulting in 94% 
of tumors being radically excised. Six months after surgery, mean FISI scores were found to be 
decreased (pre-operative: 10, post-operative: 7, p < 0.01; Figure 1), depicting an improvement 
in faecal continence. Overall when preoperative and postoperative FISI scores were compared, 
24 patients improved, 16 patients were unchanged and seven deteriorated. Operation time 
or tumor size did not influence the change in FISI score. There was a significant correlation 
between the decrease in FISI score and tumor height (p = 0.02). Reduction of FISI was signifi-
cantly greater in patients with a tumor location within seven centimetres from the dentate line 
(p = 0.01). (Table 2) Mean scores and ranges of the EuroQol EQ-5D are presented in Table 3. 
Mean general quality of life score from the patients` perspective (EQ-VAS) was found to be 
significantly higher six months after TEM (p < 0.02). The observed changes in EQ-VAS showed 
no correlation with the postoperative alterations in FISI scores or tumor characteristics. Mean 
pre-operative EQ-VAS score in our group was lower compared to the mean EQ-VAS score of the 
sex- and age-matched general population (p = 0.02). Postoperative EQ-VAS score was compa-
rable with the general population. Mean Index score (social perspective) remained the same (p 
= 0.09). Both pre- and postoperative EQ-5D index scores were similar to those of the sex-age 
matched general population. Comparing the change from baseline in FIQL scores, a statistically 
significant improvement was observed in two of the four domains (embarrassment; p = 0.03 
Table 1. Patient, tumor and procedure related characteristics.
Number of patients 47
Male/female 22/25
Median age in years (range) 67 (40-84)
Median distance from dentate line in cm`s (range) 7 (0-15)
Median tumor size in cm² (range) 20 (4-53)
Median capture of circumference of rectal wall in % (range) 40 (5-80)






























Figure 1. Mean Faecal Incontinence Severity Index (FISI) scores (±SEM) before and after transanal endo-
scopic microsurgery (TEM)




Overall 10 (2) 6 (2) p < 0.01
Duration of operation < 55 minutes (N=24) 9 (4) 7 (3) p = 0.24
Duration of operation > 55 minutes (N=23) 12 (3) 4 (2) p = 0.17
Tumors < 7 cm from dentate line (N=21) 16 (5) 5 (2) p = 0.01
Tumors > 7 cm from dentate line (N=26) 6 (2) 7 (3) p = 0.43
Median tumor size < 20 cm² (N=27) 12 (4) 6 (3) p = 0.12
Median tumor size > 20 cm² (N=20) 8 (3) 6 (3) p = 0.32
Numbers in parentheses are standard deviations. Lower values indicate better anorectal functioning.
Table 3. Mean EuroQoL EQ-5D scores.
Control group Preoperative Postoperative
Statistical 
Significance
EQ-VAS 82 (7) 77 (14) 82 (11) p = 0.02
Index score 86 (6) 84 (11) 89 (9) p = 0.09
Numbers in parentheses are standard deviations. EQ-VAS represents the patients` perspective on quality of 
life, Index score represents the societal value on quality of life. Higher scores indicate higher quality of life. 
Both scores are compared with a healthy sex- and age matched control group.
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and lifestyle; p = 0.05). The domains of lifestyle, coping and behaviour, and embarrassment 
were correlated with the FISI (all p < 0.05). (Table 4) Overall, EQ-5D and FIQL scores were not 
affected by age and gender of the patients. Surgical aspects and tumor characteristics did not 
influence the outcome. 
DISCUSSION
In rectal adenomas, TEM has emerged as the procedure of choice, because of its safety and low 
local recurrence rates. Especially compared to radical surgery TEM has proven its safety.22, 23 
However, possible adverse effects of TEM have to be addressed. The use of a rectoscope with a 
four centimetres diameter, introduced transanal, has lead to substantial scepticism regarding 
impact on anorectal functioning. In earlier studies we already showed TEM to be superior to 
total mesorectal excision regarding postoperative defecation disorders, although this did not 
result in improved quality of life. 24 In the present study TEM resulted in improved faecal conti-
nence as measured by the Faecal Incontinence Severity Index (FISI). This apparent paradox may 
be attributed to preoperative tumor symptoms as mucinous or bloody discharge, prolapse, 
tenesmi and/or urge, giving rise to incontinence-like symptoms. Postoperative improvement 
of continence was most significant in tumors within seven centimetres from the dentate line 
but disappeared in our study in tumors above seven centimetres from the dentate line. Kreis et 
al. performed manometric studies after TEM and found a significant reduction in anal resting 
pressure one year postoperative and a temporary reduction in anal squeezing pressure, result-
ing in a temporary rise in urge-incontinence. 25 Kennedy et al. found a significant reduction in 
anal resting pressure six weeks after TEM. 26 This reduction was significantly correlated with 
duration of the procedure, but mean continence score was not changed after TEM. Both of 
the above studies however did not use validated questionnaires on faecal continence, and 
therefore comparison with our study is difficult. Cataldo et al. reported on the impact of TEM 
on functional outcome and incontinence specific quality of life, using the same questionnaires. 
17 No significant alteration was found in faecal continence after TEM. The discrepancy between 
both studies may be explained by the relative short interval between the TEM procedure and 
postoperative questioning of six weeks in the Cataldo series. Also in his study, indications for 
Table 4. Mean Faecal Incontinence Quality of Life (FIQL) scores.

























TEM were heterogeneous which may have influenced results. The positive effect of TEM on 
faecal continence in our series may be explained by the differences in preoperative FISI score 
between both studies (10 versus 2.4), depicting more continence problems among the patients 
in our series. Another explanation may be the differences in tumor distance from the dentate 
line (present series median seven centimetres, Cataldo series 11 centimetres). Also in our series 
tumors were larger (median 20 cm² versus 8.75 cm²). Because tumors were larger in our series 
more extensive resections were performed, not seldom in tumors located within the sphincter 
apparatus. These latter were already shown to influence recto-inhibitory reflex, reflex sphincter 
contraction, rectal sensitivity and compliance. 16 Further analysis within our series upon this 
issue showed only tumor distance from the dentate line less than seven centimetres to be a 
significant contributing factor. These results however are based upon low number of patients 
and therefore solid conclusions cannot be drawn. Although in our study TEM resulted in a sig-
nificant improve in continence, the postoperative FISI was still worse compared to the Cataldo 
series (7 versus 2.4). Regarding quality of life, Cataldo found TEM was of no significant influence. 
In our series mean general quality of life score from the patients’ perspective, EQ-VAS, was sig-
nificantly higher after TEM. This improvement could not be explained by improved FISI-scores, 
but probably to lower pre-operative EQ-VAS scores as compared to healthy controls. Another 
explanation may be the rejoice phenomena, that is patients are relieved the tumor has been 
excised, and in most cases an adenoma was found. 27 However, because of the low number of 
invasive carcinomas in our series this is purely theoretical. The societal value of general quality 
of life, EQ-5D, remained unchanged. Measuring quality of life using the Faecal Incontinence 
Quality of Life (FIQL) questionnaires, resulted in a significant improve in two of the four FIQL 
domains (embarrassment and lifestyle). Moreover the domains of lifestyle, coping and behav-
iour, and embarrassment were all significantly correlated with the FISI.In conclusion, how are 
these results to be interpreted? This study supports the hypothesis rectal tumors give rise to 
incontinence-like symptoms, especially in low-lying rectal tumors. After the tumor is excised 
using the TEM technique, faecal continence improves. TEM itself does not improve continence, 
but also does not deteriorate faecal continence. Mean quality of life from the patients` perspec-
tive following TEM is improved.
Based on, as we know, the only two studies addressing anorectal functioning and quality of 
life after TEM in one study, it can be concluded TEM does not impair faecal continence. Also, 
quality of life is not negatively influenced by the TEM procedure itself, and therefore TEM is the 
procedure of choice in all rectal adenomas.
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Quality of life after transanal endoscopic 
microsurgery and total mesorectal excision 
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INTRODUCTION
Surgery for rectal cancer remains the only treatment modality offering a chance of cure. From 
the oncologic point of view total mesorectal excision (TME) is the gold standard. This standard-
ized and optimized surgical technique has lowered the recurrence rates and probably improved 
survival. 1-5 Sphincter saving procedures are preferred, even in very distal rectal carcinomas, in 
which low colo-anal anastomosis or inter-sphincteric techniques are used. 6-8
Unfortunately, most patients suffer adverse consequences from such radical surgery. The 
operative dissection of the rectum may damage the pelvic autonomic nerves, disturbing blad-
der and sexual function. 9-11 The closer the anastomosis to the anal canal, the worse the surgical 
and functional outcome. 12, 13 Furthermore, construction of a permanent colostomy following 
abdomino-perineal resection may be associated with clinically significant psychological prob-
lems. 14 Finally, especially in the elderly mortality after TME is substantial.15, 16
In a strive to avoid the morbidity and mortality after TME, local excision is considered a therapeu-
tic option in the treatment of well-selected patients with early rectal cancer. Several techniques 
have been developed of which transanal excision according to Parks, trans-sphincteric (or 
York-Mason) excision, trans-sacral (or Kraske) excision, and transanal endoscopic microsurgery 
(TEM), are the techniques most described. 17-23 TEM seems to be the method of choice, because 
it is safe and offers complete resection, is also possible in larger and more proximal tumors and 
comes with the lowest recurrence rates in adenomas. Points of discussion after local excision 
for early rectal cancer are the wide range of local recurrence rates from 0 to 24%, its impact on 
survival and the results of salvage surgery. 24-27 In the studies regarding TEM in T1 rectal cancer 
local recurrence rates seem limited and survival comparable to radical surgery. 28-31 However, 
definite evidence is lacking.
Performing TEM, a rectoscope is used with a diameter of four centimetres. This may attribute 
to sphincter dysfunction after TEM. The effect of the TEM procedure by means of quantitative 
studies using manometry is anecdotic, showing temporary internal sphincter dysfunction. 
However, never long-term clinical relevance could be shown. 32
Quality of life is increasingly recognised as a crucial factor when assessing clinical outcomes 
after different surgical interventions because it measures the patient’s perspective. 33-35 If 
oncologic outcome is the same in early rectal cancer after TEM and TME, QOL could be the real 
key outcome in clinical decision-making. Quality of life after TEM is sparsely studied. A recent 
study of Cataldo et al. found no significant alterations in faecal continence or disease specific 
QOL after TEM. 36
In this study we present a retrospective analysis of QOL after TEM for T1 carcinomas compared 
with a sex- and age-matched sample of patients with T+N0 rectal cancer after sphincter saving 








To determine the quality of life after TEM for T1 carcinomas, a consecutive series of 54 patients 
were studied. These patients were operated in one hospital (IJsselland Hospital) between 1996 
and 2003. Patients were analysed according to a standard protocol. The TEM technique has 
been extensively described in an earlier report. 37 Patients who underwent immediate radical 
surgery and patients with proven local or distant recurrences were excluded. Validated ques-
tionnaires were sent to eligible patients. All results were compared to the results from a sex- 
and age-matched sample of patients obtained from a consecutive series of 111 patients who 
had undergone curative (R0) sphincter saving surgery for stage I and II rectal cancer by TME 
between 1997 and 2002 at a university centre and two district hospitals. None of these patients 
had a diverting ileostomy and all were disease-free at the time of evaluation. Both groups were 
compared to a sex- and age-matched community-based sample of healthy persons.
We used the EuroQol EQ-5D, EQ-VAS and the European Organization for Research and Treat-
ment of Cancer (EORTC) QLQ-C30 and QLQ-CR38 cancer specific questionnaires. The EuroQol 
EQ-5D consisted of a so-called “index score” representing “the societal value” of the health 
state, and a visual analogue scale, the EQ-VAS, representing the patient perspective. Regarding 
QOL from patients` and social perspective, both groups were compared with a sex- and age-
matched control group of healthy persons. 38 Disease specific quality of life after TEM and TME 
was measured according to the official scoring procedures for the EORTC QLQ-C30 and EORTC 
QLQ-CR38 questionnaires. The EORTC QLQ-C30 was developed to assess the quality of life of 
cancer patients. It contains 30 items that can be computed in five functional scales (physical, 
role, emotional, cognitive and social functioning), three symptom scales, and six single items 
(fatigue, nausea and vomiting, pain, dyspnoea, insomnia, loss of appetite, constipation, diar-
rhoea and financial difficulties).  39 EORTC QLQ-CR38 was designed especially for the evaluation 
of colon cancer therapy from a patient perspective. 40 It is subdivided into two functional scales 
(i.e. body image and sexual functioning), seven symptom scales (micturition problems, gas-
trointestinal tract symptoms, chemotherapy side effects, defecation problems, stoma related 
problems and male and female sexual problems), and three single-item measures (sexual 
enjoyment, weight loss and future perspective). The validity and reliability of these question-
naires have been established in Dutch patients with colorectal cancer. In both QLQ-C30 and the 
QLQ-CR38 scores are summed within scales and rescaled from 0 to 100. A higher score indicates 
better functioning for all functioning scales and for two of the single items, sexual enjoyment 
and future perspective. A higher scale on all symptom scales and the remaining single item 
(weight loss) indicate a lower level of symptoms. 41
When appropriate, patient groups were compared using the chi-square test or Fisher`s exact 
test. Continuous variables were compared using the Mann-Whitney test. Comparisons between 
groups were also performed, using ANOVA, allowing for gender, age and time of follow-up. A 
p-value < 0.05 was considered statistically significant.
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RESULTS
TEM was performed in 54 patients. Of the original group 18 patients could not be included. 
Eleven patients died during follow up, three of them due to disease related causes (all local 
recurrence and distant metastasis). Three patients were excluded because of local recurrences, 
one patient because of a distant recurrence. One patient was excluded because during the 
same session a right hemicolectomy was performed. Two patients could not be contacted as 
they had moved abroad and their new address was not available. The questionnaires were sent 
to the remaining 36 patients. 31 questionnaires were returned, resulting in an overall response 
rate of 86%. Of the responders, 18 were male, with a median age of 71 years (range 46-90). In 
the TME group 31 patients were included, 18 male and 13 female with a median age of 70 years 
(range 51-87 years).
Patient and tumor characteristics of both groups are listed in Table 1. Regarding clinical charac-
teristics, the patients after TEM did not differ from the TME group. The median duration of time 
interval between the operation and the mailing was 28 months (range: 5 - 91 months). 
From the patient perspective, mean general quality of life score (EQ-VAS) was similar after TEM, 
TME and controls (Table 2). Also from the social perspective, the mean EQ-5D index score did 
not differ between the three groups. Scores of the EORTC QLQ-CR30 and the QLQ-CR38 for the 
patient groups are presented in Table 3 and 4. Univariate analysis showed a significant differ-
ence between the two groups regarding defecation problems. TEM patients had less defeca-
tion problems than after TME patients (p < 0.05). A trend towards better sexual functioning 
after TEM was seen, especially in male patients, although it did not reach statistical significance.
Table 1. Baseline characteristics of the responders.
TEM TME
Numbers of patients 31 31
Median age 71 (46 - 90) 71 (51 - 87)
Median Length of follow-up in months 31 (5-91) 39 (9 - 62)
Male / female (%) 58 / 42 58 / 42
Tumor (T-)stage (%) T1=31 (100)  T1=3 (10)
T2=8 (26)
T3=20 (64%)
Location tumor (0-5/ 5-15 cm from dentate line) 29/71 29 / 71
Preoperative radiotherapy (%) 0 18
Co morbidity (%) 19 19
Data are percentages or median numbers with ranges in parentheses. TEM = transanal endoscopic micro-








The major axiom of surgical treatment of rectal cancer has historically been to remove the pri-
mary lesion with adequate margins and as much of the attendant lymphatic drainage as pos-
sible. The risk of lymph node metastases and therefore the prognosis for rectal cancer depends 
on certain histopathologic criteria as depth of tumor infiltration and histological grading. 
According to this, when the tumor only invades submucosa (pT1), lymph nodes are involved 
with metastasis in 3-14 percent of patients, depending on the presence of certain unfavour-
able histopathologic criteria. 42, 43 Thus, patients with minimal invasive, histological favourable 
lesions without evidence of spread would be well served with local excision alone. Concern 
has been made on oncologic outcome after local excision for early rectal cancer. 25, 26, 44 After 
transanal excision local recurrence rates are infrequently high and the role of salvage surgery is 
Table 2. General quality of life scores.
TEM TME Population
EQ-VAS 76 (20 - 100) 70 (30 - 100) 76 (68 - 84)
EQ-5D 81 (-18 - 100) 76 (26 - 100) 76 (67 -86)
Data are mean scores with ranges in parentheses. EQ-VAS = Quality of life from the patient perspective, 
EQ-5D = Quality of life from the social perspective. TEM = transanal endoscopic microsurgery, TME = total 
mesorectal excision, Population = a sex- and age-matched, community-based sample of healthy persons 
without co-morbidity.
Table 3. Disease specific quality of life scores (EORTC QLQ-C30).
TEM TME
Mean Median (range) Mean Median (range)
Physical function 78 87 (0 - 100) 83 90 (20 - 100)
Role function 81 100 (0 - 100) 80 83 (0 - 100)
Emotional function 82 92 (0 - 100) 82 92 (17 - 100)
Cognitive function 84 100 (0 - 100) 86 100 (17 - 100)
Social function 60 67 (0 - 100) 69 67 (0 - 100)
Global health status 73 83 (33 - 100) 74 75 (17 - 100) 
Fatigue 76 89 (0 - 100) 80 81 (11 - 100)
Nausea/vomiting 90 100 (0 - 100) 95 100 (17 - 100)
Pain 80 100 (0 -100) 89 100 (0 -100)
Dyspnoea 87 100 (0 - 100) 87 100 (0 - 100)
Sleep disturbance 76 100 (0 - 100) 82 100 (0 - 100)
Appetite loss 93 100 (33 - 100) 97 100 (33 - 100)
Constipation 93 100 (33 - 100) 85 100 (0 - 100)
Diarrhoea 86 100 (0 - 100) 89 100 (0 - 100) 
Financial worries 94 100 (33 - 100) 94 100 (0 - 100)
A high subscale score indicates low distress and good functioning. TEM = transanal endoscopic microsur-
gery, TME = total mesorectal excision.
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uncertain.27 The main problem when reviewing the literature on local excision for early rectal 
cancer is the diversity of used techniques and varying patient and tumor selection. Compared 
to other local techniques TEM has emerged as the method of choice in T1 early rectal cancer 
as it yields lower recurrence rates. 45 Moreover, comparable results to radical surgery can be 
achieved with TEM. 28, 29 Nevertheless, definite evidence for TEM in T1 early rectal cancer is still 
lacking. When the TEM procedure is considered a therapeutic option, this latter aspect should 
be discussed in detail with every patient before obtaining informed consent.
It seems reasonable to assume that quality of life after local excision using the TEM technique 
is better than after radical resection. However, no prospective trial has been initiated to investi-
gate this assumption. As for radical surgery, several studies have shown that functional results, 
especially bladder and sexual functioning, are bad. 9-11
In the present study QOL after TEM is compared to QOL after radical resection, and to our 
knowledge is the first study to address this subject. Although being retrospective and hence 
limited, several remarkable findings have come forward. Both after TEM and TME patients rank 
their quality of life as high as that in the population-based reference group. Moreover, QOL 
was no different between TEM and TME patients. This finding might be due to methodologi-
cal shortcomings of our study design: its retrospective nature, the relatively small number of 
patients and the lack of control measurements before treatment limit the present study. 
Another plausible explanation could be the fact that several patients were only diagnosed to 
have a carcinoma after the TEM procedure. At that point patients are told to have rectal cancer 
and TME is the gold standard. They are offered the choice between an additional TME and 
follow-up only. When the patient chooses for follow-up the rectum is re-examined every three 
Table 4. Disease specific quality of life scores (EORTC QLQ-CR38).
TEM TME
Mean Median (range) Mean Median (range)
Micturition problems 79  77 (22 - 100) 81  78 (44 - 100) 
Gastrointestinal problems 81  87 (33 - 100) 80  80 (40 - 100)
Weight loss 92  100 (33 - 100) 94  100 (33 - 100)
Body image 90 100 (44 - 100) 88 100 (0 - 100) 
Defecation problems 91  90 (57 - 100) * 77  80 (47 - 100) *
Stoma problems - - - -
Chemo side-effects 89  100 (22 - 100) 90  89 (22 - 100)
Sexual function 27 17 (0 - 100) 24 17 (0 - 83)
Sexual enjoyment 61 67 (0 - 100) 53 67 (0 - 100)
Male sex problems 62  83 (0 - 100) 46  42 (0 - 100) 
Female sex problems 89  92 (33 - 100) 81  83 (33 - 100)
Future perspective 71 67 (0 - 100) 72 67 (0 - 100)
A high subscale score indicates low distress and good functioning. TEM = transanal endoscopic microsur-







months by means of digital rectal examination, rigid rectoscopy and endorectal ultrasound. 
This may burden them to the feeling of being at risk of developing a local recurrence with 
its impact on QOL. Furthermore, the relatively high QOL, observed among our patients after 
TME, might be explained by the fact that the measurement followed their earlier diagnosis of a 
life-threatening disease, which changed their perceptions of the length of life, thereby shifting 
their expectations and priorities with regard to life fulfilment. Successful treatment therefore 
might result in a higher quality of life as reported by the patient. This effect, known as ‘rejoice’, 
has been noted from the beginning of quality-of-life research. 46
Functional outcome after rectal surgery is frequently impaired. Most studies report sustained 
reduction in resting sphincter pressures after sphincter saving surgery with TME. This decrease 
has been attributed to the dilatation performed when the circular stapler is inserted. However, 
there is strong evidence that direct sphincter trauma is not a major cause for dysfunction. Several 
manometric studies have suggested neurogenic injury rather than morphologic damage as the 
explanation for postoperative functional disorder. 47 Hallgren et al. investigated the changes in 
resting sphincter pressure during the different stages of restorative proctocolectomy and either 
hand sewn or stapled pouch-anal anastomosis. 48 In both techniques the resting pressure was 
reduced in a sequential manner during the surgical procedure, with an immediate decrease in 
pressure after division of the superior rectal artery, a further reduction after full mobilization of 
the rectum, followed by another equally large drop at the final stage after construction of the 
anastomosis by either technique.
Because of the 4 cm diameter of the rectoscope, the prospect of continence following TEM was 
of concern. Although a significant decrease in both anal resting pressure and squeeze pressures 
occurs initially, these pressures return to pre-operative values at a mean of four months after 
TEM. 32, 36, 49 A possible explanation might be the fact that TEM keeps the neural autonomic 
pathways regulating sphincter tone intact. In our study, after TEM, patients had significant less 
defecation problems, as found with the EORTC QLQ-CR38 questionnaire. In a recent study a 
correlation between alterations of the anal sphincters and the functional outcome could 
not be demonstrated. 50 Therefore the interesting question arises whether the postoperative 
compliance and sensory perception are the determining functional factors. It is well known 
that the functional outcome after low anterior resection improves with time. It has been shown 
that this improvement is associated with an increase of compliance. 51-53 The better functional 
outcome in TEM patients might be due to the fact that the original rectum remains unaffected. 
Several authors have suggested that radiation to soft tissues of the pelvis worsens postopera-
tive neorectal function. 54 However, in the present study only 18 percent of TME patients had 
preoperative radiotherapy. This low percentage might mitigate the differences in functional 
outcome in this study.
In a recent report it was stated that sexual problems after radical surgery for rectal cancer are 
common, and efforts to prevent and treat it should be increased. 9 In our study there was a 
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trend towards better sexual functioning after TEM, especially in male patients, although it never 
reached statistical significance.
On the basis of this study, despite the methodological shortcomings, it might be concluded 
that there is no difference in impact on QOL from the patients` and social perspective after 
TEM and TME. Defecation problems after TEM are less encountered than after TME. This dif-
ference could play a role in the choice of surgical therapy in early rectal cancer. One should 
keep in mind the retrospective nature of the study and future prospective studies are needed 
to answer the question whether TEM for low risk T1 carcinoma is superior to TME regarding 
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INTRODUCTION
Local excision of rectal adenomas (TVA) is a validated treatment modality. Concern has been 
made regarding local recurrences after local excision, but with the introduction of transanal 
endoscopic microsurgery (TEM) this risk has become minimal and even larger and more proxi-
mal located TVA can be excised. 1-3 In these larger presumed benign rectal lesions, based on 
preoperative biopsy, definite histopathology reveals a carcinoma in up to 34% of tumors. 4, 5 As 
a result patients with missed carcinoma need to undergo additional radical surgery by means 
of total mesorectal excision (TME). Although evidence is lacking, prior TEM procedures may 
burden immediate radical surgery with possible higher morbidity, including increased risk on 
a (permanent) stoma. Moreover, this unexpected histopathological finding and the need for 
additional surgery impede patients’ satisfaction. Finally, oncologic outcome in this subgroup of 
patients is questionable. 6, 7
Extensive efforts have been made to improve preoperative diagnosis of rectal tumors, with 
computerized tomography (CT), magnetic resonance imaging (MRI) and endorectal ultrasound 
(ERUS) as the techniques most commonly used. Each adjunct has its limits, but ERUS seems the 
most adequate with accuracy rates for tumor infiltration (T-stage) ranging from 64-95%. 8-13
If ERUS, however, is to be considered essential in preoperative staging, accuracy may not be 
the only relevant issue. Feasibility of ERUS in all rectal tumors referred for local excision and the 
additional value of ERUS in therapeutic decision-making are equally important. In this prospec-
tive study we investigated the feasibility of ERUS in all TVA referred to our hospital for TEM. 
Also the additional value of ERUS in diagnosing invasive carcinomas and its role in therapeutic 
decision making are studied.
PATIENTS AND METHODS
From April 2000 to May 2006 in 264 consecutive patients with 268 tumors preoperative biopsy 
revealed a TVA. In all tumors ERUS was intended. The group consisted of 128 males and 136 
females. Median age was 70 years (range 29-91 years) and median distance from the dentate 
line to the distal tumor margin was 8 cm (0-20 cm). Fifty-six tumors were located in the lower 
third of the rectum (0-5 cm), 133 in the middle third (5-10 cm) and 79 in the upper third (10-15 
cm). Median tumor area was 12.3 cm² (0.25-156 cm²). In 69 tumors it concerned residual tumor 
tissue after recent endoscopic treatment or a recurrent tumor.
Two hours prior to ERUS a cleansing enema was given. Patients were placed in lithotomy posi-
tion and digital rectal examination and rigid rectoscopy were performed. After inspection of 
the tumor, the tip of the rectoscope was positioned proximal to the upper margin of the tumor 
and the ERUS–probe was introduced via the rectoscope with the tip of the probe outside the 







documented on videotape. The ultrasound equipment used was a B&K Medical Scanner (Nae-
rum, Denmark) Type 2101 with a type 1850 rotating endosonic probe with a 10 MHz crystal.
If the tumor could not be reached or passed completely during rectoscopy, or if technical 
problems occurred, such as inability of cleansing the rectum or equipment failure, the tumor 
was considered not assessable. In assessable tumors all rectal wall layers had to be visualized 
without artefacts before considering ERUS conclusive. Ultrasound staging was compared with 
definite histopathological findings.
Statistical analysis was performed using the SPSS® version 11.0 (SPSS, Chicago, Illinois, USA). 
Continuous variables and percentages were compared between groups using the Mann-
Whitney test or Chi-Square test, respectively. A p-value of 0.05 (two-sided) was considered 
as the limit of significance and 95% confidence intervals (95% CI) are calculated for various 
percentages. Kappa statistics were calculated to quantify the agreement between ERUS- and 
histopathological stages.
RESULTS
Of the 268 tumors in this study 231 (86%) were assessable for ERUS. Median distance from 
the dentate line in not assessable tumors was 11 cm, which was significantly different from 
assessable tumors, with a median distance of 7 cm (p < 0.001). Of the not assessable tumors 
62% were located more than 10 cm proximal from the dentate line. There was no difference 
in median tumor area between assessable and not assessable tumors. Also the percentage of 
recurrent/residual tumors was not different. (Table 1) 
In 16 tumors ERUS was not performed because of a technical failure (patient incontinence n= 
8, inability of cleansing the rectum n=4, equipment failure n=4). Twenty-one tumors were not 
assessable because they could not be reached or passed due to stenosis and angulation in the 
rectosigmoid, or because the tumor was too voluminous. 
In 210 of 231 assessable tumors (91 %) ERUS was considered conclusive. (Table 2) Fifteen of the 
21 tumors in which ERUS was not conclusive were residual or recurred after prior endoscopic 
treatment (71%). Compared to the tumors in which ultrasound staging was considered conclu-
sive, this proportion was significantly higher (p < 0.001).
Definite histopathological staging revealed TVA in 166 tumors (79%), T1 rectal carcinoma in 30 
(14.3%), T2 rectal carcinoma in 13 (6.2%) and T3 rectal carcinoma in 1 (0.5%). Overall accuracy of 
ERUS is 84%. (Table 3) ERUS correctly staged 147 tumors as TVA, with a corresponding sensitivity 
of 89%. (Table 4) ERUS correctly staged 38 tumors as invasive with a corresponding sensitivity 
of 86%. Positive and negative predictive values were 96% and 67% respectively.
If only TVA are considered indications for local excision, based on preoperative biopsy 44 
tumors would have been undertreated with TEM, as definite histopathology revealed a car-
cinoma (21%; 95% CI: 15-26%). Based on ERUS 6 tumors would have been undertreated (3%; 
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95% CI: 1-6%). This reduction in undertreatment is statistically significant (p < 0.01). Based 
on preoperative biopsy no tumor would have been overtreated with TME, whereas based on 
ERUS 19 ultrasonically presumed T2/T3 carcinomas would have been overtreated (9%; 95% CI: 
5-13%). This increase in overtreatment is statistically significant (p < 0.01).
If TVA and T1 carcinomas are both considered indications for local excision, based on preop-
erative biopsy 14 tumors would have been undertreated with TEM (7%; 95% CI: 4-11%). Based 
on ERUS, 6 ultrasonically presumed tumors suitable for TEM would have been undertreated 
(3%; 95% CI: 1-6%). This reduction in undertreatment is significant (p < 0.01). Based on pre-
operative biopsy no tumor would have been overtreated with TME, whereas based on ERUS 9 
ultrasonically presumed T2/T3 carcinomas would have been overtreated (4%; 95% CI: 2-8%). 








Local excision of rectal TVA is the method of choice. As a tertiary referral centre for TEM, we 
are frequently encountered with tumors considered suitable for local excision using the TEM 
technique. TEM has proven to be a safe procedure for TVA, with the possibility to excise larger 
and more proximal located tumors. 1, 2 In presumed rectal TVA, especially in larger tumors, 
definite histopathology may reveal a carcinoma. In case a carcinoma was missed with biopsy, 
immediate radical surgery after local excision might be more difficult with possibly increased 
morbidity. Moreover, in distal located tumors prior local excision could decrease the possibility 
on sphincter saving surgery. Finally, oncologic outcome in this subgroup of patients is ques-
tionable. 6, 7 For these reasons adequate preoperative staging is of major importance.
Of all frequently used staging modalities in rectal tumors ERUS is the most promising, as 
accuracy concerning tumor invasion depth is higher compared to CT scanning and at least as 
Table 5. Agreement of ERUS and histopathological staging in diagnosing TVA and T1 carcinomas.
                                                          Histopathological T-staging
ERUS T-staging pTVA/T1 pT2/T3 Total
uTVA/T1 187 6 193
uT2/uT3 9 8 17
Total 196 14 210
Sensitivity 95% (187/196), Kappa-coefficient 0.48, specificity 57% (8/14), positive predictive value 97% 
(187/193), negative predictive value 47% (8/17).
Table 3. Agreement of preoperative ERUS with definite histopathological T-staging.
                                           Histopathological T-staging
ERUS T-staging pTVA pT1 pT2 pT3 Total
uTVA 147 4 1 1 153
uT1 14 22 4 0 40
uT2 4 2 7 0 13
uT3 1 2 1 0 4
Total 166 30 13 1 210
Overall accuracy 84% (176/210), Kappa coefficient 0.59, sensitivity in diagnosing: TVA 89% (147/166), T1 
carcinomas 73% (22/30), T2 carcinomas 54% (7/13).
Table 4. Agreement of ERUS and histopathology in diagnosing tubulovillous adenomas.
                                                          Histopathological staging
ERUS T-staging pTVA pT1/T2/T3 Total
uTVA 147 6 153
uT1/T2/T3 19 38 57
Total 166 44 210
Sensitivity 89% (147/166), Kappa-coefficient 0.68, specificity 86% (38/44), positive predictive value 96% 
(147/153), negative predictive value 67% (38/57).
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accurate as MRI. 8-10 The additional value of ERUS in preoperative staging, compared to other 
modalities, is expressed by the power to discriminate TVA from invasive carcinomas. ERUS was 
already shown to be able to correctly establish a cancer diagnosis in 81% of the missed carci-
nomas at biopsy. 14 These results are of major importance as treatment options, local excision 
versus radical surgery, are to be discussed with every patient. In rectal carcinomas TME is the 
gold standard. Although evidence is sparse, in T1 rectal carcinomas the role of TEM has been 
re-appraised. 15, 16 If both TVA and T1 rectal carcinomas are considered suitable candidates for 
local excision, ERUS might be of additional value in discriminating these two from more inva-
sive carcinomas. However, especially in larger and more proximal tumors ERUS may be more 
difficult and if ERUS is considered a useful preoperative adjunct, feasibility in all rectal tumors 
has to be investigated. One study suggested that in 13% of all rectal tumors ERUS was not 
feasible. The percentage of not assessable tumors increased from 11% in distal tumors (0-4 cm 
above anocutaneous line) to 34% in proximal located tumors (12-16 cm above anocutaneous 
line). However, uniformity regarding the technique of ERUS lacked. Moreover, physicians were 
allowed not to perform ERUS if considered without additional value. This resulted in 63% of 
all rectal tumors in which ERUS was not performed. Moreover, only 10% of all tumors in which 
ERUS was performed were located proximal in the rectum. In our series in all tumors referred for 
local excision by means of TEM, ERUS was intended. In 86% of all tumors ERUS was technically 
feasible. If not feasible, distance from the dentate line proved to be a significant contributing 
factor. Proper interpretation of ERUS imaging was possible in 78% of all tumors. The only sig-
nificant factor negatively influencing interpretation of ERUS imaging was residual or recurrent 
disease, especially after recent (endoscopic) manipulation (p < 0.001). Several authors already 
stated that tumor biopsy or (endoscopic) manipulation prior to ERUS should be avoided if 
on clinical grounds local excision is considered suitable. 11 This could lower the proportion of 
patients in which ERUS is not conclusive. 
Because of the possibility to excise larger tumors with TEM in a large proportion of presumed 
adenomas a carcinoma is found. In our series in 21% of tumors an unexpected carcinoma was 
found, which is comparable to other series. 4, 5 The role of ERUS in preoperative evaluation of 
presumed TVA is significant. In a relatively large review ERUS correctly established a cancer 
diagnosis in 81% of preoperative (biopsy) misdiagnosed TVA. The need for additional surgery 
and other associated problems caused by misdiagnosis could be decreased from 24 to five 
percent. 14 These results are confirmed in our study, with 86% of missed carcinomas on biopsy 
corrected with ERUS. In TVA sensitivity rates of 89% and specificity rates of 86% can be achieved. 
The main advantage of ERUS in presumed adenomas is the high positive predictive value of 
96%, meaning if ERUS confirms the tumor as TVA only in four percent an invasive carcinoma is 
found at definite histopathological staging.
The question which rectal tumors are suitable for local excision using the TEM technique is 
still unanswered. In rectal cancer TME is the gold standard, but evidence, although anecdotic, 







between TVA and T1 carcinomas may be of less priority but the difference between T1 and more 
invasive carcinomas is essential. Sailer et al. stated if TVA and T1 carcinomas are considered one 
ultrasonic entity, ERUS reaches a sensitivity of 81% and a specificity of 98%.11 They concluded 
ERUS is helpful in therapeutic decision-making between local excision and radical surgery. In 
our series sensitivity in diagnosing TVA and T1 carcinomas was 95%. In 14 tumors (7%) a T2 
or more invasive carcinoma was found at definite histopathology. Preoperative biopsy found 
none of these carcinomas, whereas ERUS correctly classified eight of these tumors as uT2/uT3. If 
ERUS findings would have been used as adjunct in therapeutic decision-making, 57% of missed 
T2 and T3 carcinomas on biopsy could have been spared prior local excision. This absolute 
risk reduction in undertreatment, 7 versus 3 per cent, was statistically significant (p < 0.01). 
However, ERUS classified nine tumors as not suitable for local excision (uT2 or higher), which 
proved to be adenomas (five) or T1 carcinomas (four). This increase in possible overtreatment, 
0 versus 4 per cent, was also statistically significant (p < 0.01). This overstaging is also found in 
other series and is a major drawback of ERUS. 11 
In conclusion, based upon this study ERUS is technically feasible in almost all rectal tumors in 
which preoperative biopsy shows tubulovillous adenoma. Proper ERUS interpretation is pos-
sible in 78% of all presumed rectal TVA. ERUS can discriminate between adenomas and invasive 
carcinomas and has, next to biopsy findings, a substantial additional value in recognizing TVA 
suitable for local excision. If a carcinoma is suggested with ERUS, one has to discuss treatment 
options, local excision versus radical surgery, with every patient. This study has shown that if 
T1 rectal carcinomas are considered suitable candidates for TEM, ERUS has a major additional 
value in preoperative staging.
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INTRODUCTION
Colorectal cancer is one of the leading causes of mortality and accounts for ~300,000 new cases 
per year in Europe and the United States. 1 Approximately 25% of these cases are rectal cancers, 
and the incidence of its benign precursor lesion, adenomas, is far higher. Total mesorectal 
excision is the gold standard to treat carcinomas, transanal endoscopic microsurgery (TEM) 
is the method of choice to treat sessile adenomas. 2-4 Although it has not yet been proven, 
T1 rectal carcinomas may be good candidates for TEM without compromising oncologic out-
come. 5-7 On the other hand, an invasive carcinoma (beyond the muscularis mucosae) is found 
after local excision in a large proportion of presumed benign tumors, which shows the need 
for more precise staging. 5, 8 Several possible imaging techniques have additional value, and 
endorectal ultrasound seems most promising; however, not all cases are eligible for endorectal 
ultrasound, and overstaging is a serious problem. 9 It should be noted that TEM-treated cases 
of early rectal cancer mostly consist of adenoma tissue. Thus, there is a need for additional 
preoperative staging methods that can accurately facilitate therapeutic decision-making in the 
treatment of rectal tumors. Ideally, a combination of methods should be able to reliably discern 
benign adenomas from adenomas containing a carcinoma focus, as well as predict lymph node 
metastasis. 
Chromosomal instability is the main characteristic of many different tumor types, including 
rectal cancer. To date, many studies have been done in colorectal cancer to assess chromosomal 
gains, losses or LOH. Commonly involved regions in (colo-) rectal cancer are 5q, 8, 13q, 17p, 
18q and 20q, as established by different groups. 10-14 Other studies specifically analyzed rectal 
cancer precursor lesions and found that commonly involved chromosomal aberrations are 
already frequent in adenomas or are correlated with high-grade dysplasia. 15-18 Several studies 
identified intratumor heterogeneity, which is characterized by patterns of different chromo-
somal aberrations in different tumor areas of the same lesion. 19, 20
In a previous study, we used single nucleotide polymorphism (SNP) arrays to detect copy 
number aberrations and LOH in rectal adenomas and carcinomas at different clinical stages. 12 
Considering the frequent malignant events, gain of 8q, 13q and 20q, and loss of 17p and 18q, 
we have built a rectal cancer progression model. In addition, we found that (combinations of ) 
these “malignant” events were increasingly found in adenoma fractions of carcinoma cases in 
comparison with pure adenomas. We now did a systematic comparison of chromosomal insta-
bility patterns in adenoma and carcinoma fractions in the same lesion of early rectal cancer 
cases that were treated by TEM. The effect of intratumor heterogeneity in a partly overlapping 
set of tumors was assessed by chromosomal instability analysis of three different ex vivo core 









Material from 36 rectal carcinomas was obtained. These tumors were preoperatively classified 
as adenomas, but in all cases, definite histopathology revealed the presence of a carcinoma. All 
patients were treated using the TEM technique at the IJsselland Hospital (Capelle a/d IJssel, the 
Netherlands) or Reinier de Graaf Hospital (Delft, the Netherlands). None of the patients received 
(neo-) adjuvant radiotherapy or chemotherapy. All samples were reviewed by a pathologist 
(H.M.), dysplasia was scored, and tumor cell percentage was assessed (50-80%). From these 
tumors, we analyzed an adenoma (also indicated as A/C), a carcinoma (also indicated as C/C), 
and a normal tissue fraction. For comparison, we used data from 21 pure rectal adenomas (also 
indicated as A/A) from a previous study. 12 
For intratumor heterogeneity analysis, three core biopsies were taken postoperatively, ex vivo, 
from 13 of the carcinoma cases and 5 of the pure adenoma cases at the surface of the tumor. 
These biopsies were randomly taken and snap frozen in liquid nitrogen. Biopsies contained 
either adenoma or carcinoma tissue. 
The local medical ethical committee approved the study (protocol number P04.124). Table 1 
shows all sample characteristics.
dna isolation
Formalin-fixed, paraffin-embedded (FFPE) tissue from the adenoma and carcinoma fractions 
was analyzed. DNA was extracted as previously described. 21 Briefly, three tissue punches (0.6 
mm diameter) were obtained using a tissue microarrayer (Beecher Instruments, Sun Prairie, 
WI), and DNA was isolated with proteinase K. Formalin-fixed, paraffin-embedded DNA was 
subsequently cleaned up using the Genomic Wizard kit (Promega). 
DNA from the frozen tumor biopsies was extracted as previously described  using the Genomic 
Wizard kit. 12
All DNA concentrations were measured with the PicoGreen method (Invitrogen-Molecular 
Probes, Breda, The Netherlands), and DNA quality was checked on a 1% agarose gel. 
array analysis
The use of SNP arrays is a well-established method for copy number and LOH analysis. There-
fore data were not validated with cytogenetics in the present study. Validation studies are well 
documented by us and others. 22-24
For each cell isolate, 1 µg of DNA was used for the BeadArrays. Illumina BeadArrays, in combina-
tion with the linkage mapping panel version 4_v3 or version 4_v4B (Illumina, San Diego, CA), 
were used and respectively contained 5,861 or 6,008 SNP markers distributed evenly over the 
genome with an average physical distance of 482 kb. Samples were prepared according to the 
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Table 1. Patient characteristics.







1 M 63 8 LC 2 x
2 F 70 3.5 LC 1 x x
3 F 89 HC 1
4 F 77 1.5 HC 1 1 x
5 F 56 7.5 LC 3 1 aaa
6 M 59 4.5 LC 2
7 M 77 7 LC 2
8 M 55 3 LH 1 aaa
9 F 79 HC 2
10 M 61 7 LC 1 aaa x x
11 M 74 2.5 HC 1
12 M 60 5 HC 1
13 F 56 3.8 HC 1
14 F 77 4 LHC 2
15 F 73 3 HC 1
16 M 79 4 HC 1 ccc
17 M 61 10 LH 1
18 F 56 8.6 LH 1 aaa x
19 M 45 5 LC 1
20 M 60 2.5 LC 1
21 F 49 2 LC 1
22 M 68 HC 2
23 F 70 1.5 LC 1 aac
24 F 58 1 LHC 1
25 M 46 5 HC 2 1 acc
26 M 53 3.5 HC 2 ccc
27 F 47 HC 2
28 F 83 9 HC 1 x x
29 F 73 2 HC 1 aaa
30 F 65 HC 1 aaa
31 M 64 5 HC 2
32 M 71 6.5 LC 1
33 M 80 1 HC 1
34 F 58 3 HC 1
35 M 70 11 HC 1 x
36 F 73 8 LH 1 x
37* M 82 13.5 L 0
38 M 75 7.5 H 0
39 F 72 5 H 0
40 M 62 7.5 H 0
41 M 75 8 H 0
42 M 78 4 H 0
43 F 87 2 L 0 aaa
44 M 61 5 H 0
45 F 87 5 H 0
46 M 67 9 L 0
47 F 74 2 L 0 aaa
48 F 68 2 L 0
49 F 52 6 L 0 aaa
50 M 53 9 L 0 aaa
51 F 52 6.5 L 0
52 F 63 7.3 L 0
53 M 60 6 L 0
54 M 79 5 L 0 aaa
55 M 73 6.5 H 0
56 F 40 11 L 0
57 F 81 4.5 H 0
58 M 69 7.5 1 aaa
59 M 73 3.5 1 aac
60 F 83 2 2 ccc
NOTE: x= a recurrence or distant metastasis. Abbreviations: L= adenoma with low-grade dysplasia; H= ad-
enoma with high-grade dysplasia; C= carcinoma; a= adenoma tissue; c= carcinoma tissue.







Goldengate assay. 25 Gene calls were extracted using the gene calling programs GeneCall and 
GTS Reports (Illumina, San Diego, CA). 
copy number and lOH analysis
Copy numbers were determined based on intensity of the individual SNPs. 23 LOH was ana-
lyzed by comparing the genotypes from paired normal and tumor DNA. Analyses were done 
using the R-package beadarraySNP. In addition, chromosome visualization of LOH was done 
in Spotfire DecisionSite (Spotfire, Somerville, MA). 26 LOH was calculated as described1. Briefly, 
LOH was computed from the gene call score and the gene train score output of GeneCall and 
GTS Reports (Illumina, San Diego, CA). LOH was called for high quality heterozygous SNPs in 
the normal tissue (gene call score/gene train score ratio > 0.8) that were, in the paired tumor, 
homozygous or showed a gene call score/gene train score ratio of <0.8. Only LOH at a stretch of 
two or more SNPs was scored. 26 When both physical loss and LOH were detected at a specific 
region, the LOH detected is an additional indication of physical loss. In the case where no copy 
number change was detected, LOH was interpreted as copy neutral LOH.
aPc and Kras mutation screening
APC and KRAS mutation detection were performed as described. 27 PCR product (5-10 ng) was 
sequenced with 6 pmol of M13 forward or reverse primer on an ABI 3700 DNA Analyzer using 
Big Dye Terminator Chemistry (Applied Biosystems, Forster City, CA). Sequences were analyzed 
with Mutation SurveyorTM DNA variant analysis software (version 2.61 Softgenetics, State Col-
lege, PA).
p53 and smad4 immunohistochemical analysis
Triplicate tissue cores from tumor areas, selected by a pathologist (H.M.) based on (H&E)-stained 
slides, were taken from each specimen (Beecher Instruments, Silver Springs, MD, USA). These 
punches, which had a diameter of 0.6 mm, were arrayed on a recipient paraffin wax block using 
standard procedures. 28, 29 A paraffin sectioning aid system (Instrumedics Inc., Hackensack, NJ) 
was used to facilitate cutting 5-µm sections of the tissue micro-array. After antigen retrieval 
(microwave oven treatment for 10 minutes in 10 mmol/L citrate buffer pH 6.0 (p53) or Tris-EDTA 
pH 8.0 (SMAD4)), endogenous peroxidases were inactivated by 1% H2O2/PBS. Sections were 
incubated overnight at room temperature with mouse anti-human monoclonal antibodies 
directed against p53 (clone D0-7, 1:1000 dilution; NeoMarkes) or SMAD4 (clone B-8, 1:100 dilu-
tion; Santa Cruz Biotechnology). The sections were then incubated and stained with a biotinyl-
ated secondary antibody in PBS/bovine serum albumin 1% (p53) or Envision HRP-ChemMate 
1  R. van Eijk et al. Genotyping and LOH analysis on archival tissue using SNP arrays. In Genomics - Method 
Express, M. Starkey and R. Elaswarapu, eds. (Bloxham: Scion Publishing); 2008, in press.
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kit (SMAD4; DAKO). Diaminobenzidine tetrahydrochloride was used as a chromogen for p53 
staining. The slides were counterstained with hematoxylin. p53 was scored in four different 
categories based on any level of nuclear staining: 1% to 25% positive nuclei (indicative for a 
wildtype status), 25% to 75% positive nuclei, > 75% positive nuclei (the latter two mostly indica-
tive for a mutation) or completely negative (uninformative). SMAD4 was scored in the following 
categories: no nuclear staining with a positive internal control (total loss), weak nuclear staining 
(down regulation) and moderate to strong nuclear staining (positive). 
statistics
Student’s t-test was used to compare means of continuous variables between two groups. χ2 
tests were done to test significance between groups for specific loss and gain events. Physical 
loss and copy neutral LOH were considered as identical events in these analyses. Correlations 
between two tumor fractions were computed using Pearson’s correlation coefficients. For all 
analyses, p-values of < 0.05 were considered as significant. All these analyses were done using 
Statistical Package for the Social Sciences 12 (SPSS). 
RESULTS
chromosomal aberrations
In a previous study, we typed copy number profiles using SNP arrays in 77 fresh frozen tumors of 
different stages. 12 We subdivided the adenoma tissue into pure adenomas (A/A) and adenoma 
fractions of cases with a carcinoma focus (A/C). The carcinoma tissue was subdivided in tumor 
samples consisting of a mixture of adenoma and carcinoma tissue (AC/C), carcinoma tissue 
alone (C/C) and primary tumors in cases with lymph node metastasis (C/C (N+)). Importantly, 
the latter two contained no or only minimal adenoma tissue, whereas the A/C cases consisted 
predominantly of adenoma tissue. We found five specific chromosomal aberrations (gain of 8q, 
13q and 20q and loss of 17p and 18q), which could discriminate adenomas from carcinomas.
With the aim of studying the early aberrations already present in the adenoma fraction of 
carcinoma cases, we assessed copy number alterations and LOH in paired adenoma (A/C) and 
carcinoma (C/C) formalin-fixed, paraffin-embedded tissues of 36 TEM treated rectal carcinomas. 
In two cases, two different adenoma fractions were identified, and for four cases, the carcinoma 
fraction was too small to be analyzed; therefore, both the adenoma fraction with low and high 
grade dysplasia were analyzed, finally leading to a total number of 32 C/C fractions and 42 
A/C fractions. Table 2 shows the most frequent chromosomal changes per sample group; in 
supplementary Table 1, all genomic and genetic abnormalities are shown for each case. The 
A/C and C/C fractions were compared with each other and with the pure adenomas (A/A) from 
the previous study. 12 From that study, we learned that only specific adenoma events (loss of 




























loss 1p36 19 39 29 33 38 n.s. n.s. n.s. n.s.
loss 4q32-pter 29 11 13 12 22 n.s. n.s. n.s. n.s.
LOH/loss 5q 29 50 38 43 38 n.s. n.s. n.s. n.s.
gain 7p15-11 29 17 13 14 25 n.s. n.s. n.s. n.s.
gain 12q13 19 22 8 14 12 n.s. n.s. n.s. n.s.
Carcinoma events
gain 8q22-24 10 17 21 19 41 n.s. n.s. 0.01 0.042
gain 13q 5 17 33 26 59 n.s. 0.049 < 0.001 0.005
loss 17p 14 28 33 31 44 n.s. n.s. 0.02 n.s.
loss 18q12-22 14 33 46 40 66 n.s. 0.028 < 0.001 0.031
gain 20q 10 33 46 40 47 n.s. 0.007 0.003 n.s.
gain 13q combined
0 12 13 12 41 n.s. 0.037 < 0.001 0.005
with loss 18q12-22
Lymph node metastasis
gain 1q23 0 0 0 0 9 n.d. n.d. n.s. 0.023
Other progression events
8p loss 5 6 8 7 34 n.s. n.s. 0.007 0.003
14q loss 10 0 8 5 22 n.s. n.s. n.s. 0.024
15q loss 0 6 8 7 25 n.s. n.s. 0.003 0.032










































































n.s. 0.011 < 0.001 n.s.
Abbreviations: n.s.= not significant; n.d.= not determined. *p-values were computed by χ2 test. † For both 
mutational analysis and immunohistochemistry, not all cases could be typed, due to technical limitations. 
For each group the number of typed individuals with a mutation/staining and the total number typed are 
indicated in brackets. ‡ Reduced expression of SMAD4 protein expression (SMAD4-faint); completely nega-
tive for SMAD4 protein expression (SMAD4-neg).
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cases. In the current study, we observed that the carcinoma or “malignant” events were all 
significantly different between the C/C and A/A groups (Table 2). Three of the five events were 
also significantly different between the A/C and A/A groups (13q gain, 20q gain, and 18q12-
22 loss) and between the C/C and A/C groups (8q22-24 gain, 13q gain, and 18q12-22 loss). 
In addition, 13q gain combined with 18q loss was significantly different between the groups. 
Moreover, additional carcinoma progression events were identified in this study: loss of 8p, 14q 
and 15q and gain of 19q were all increased in carcinoma fractions (C/C) in comparison with 
their adenoma counterparts (A/C).
mutations of aPc and Kras
To supplement chromosomal instability data, mutational status of colorectal cancer genes APC 
and KRAS was studied. A major function of the APC protein is β-catenin degradation. Mutations 
in APC result in the loss of β-catenin binding sites; however, when the mutation is in the muta-
tion cluster region, one or two active β-catenin binding sites are retained. Albuquerque et al. 
posed that the position and type of the second hit on APC depends on the localization of the 
first hit. 30 Patients with the first mutation around codon 1300 acquire the second hit by allelic 
loss, whereas patients with a first mutation elsewhere acquire truncating mutations within the 
mutation cluster region rather than loss/LOH. The amount of remaining β-catenin binding sites 
might lead to a different biological behavior of the tumors. For KRAS, the type of mutation was 
also suggested to be of significance. In a large data set, the valine alteration was correlated with 
shorter survival in relation to other mutations. 31 
In the pure adenomas, we observed high percentages of APC and KRAS mutations (61% and 
53% respectively), comparable with frequencies in the A/C (62% and 67%) and C/C tumor 
fractions (50% and 46%, Table 2). For APC, we examined whether patients with 5q retention 
had other types of APC mutations compared with cases with 5q LOH/loss. In the cases with 
5q LOH/loss, we observed that 64% had an APC mutation, whereas cases with 5q retention 
showed a frequency of 52% (not significant). There was no difference in the type of mutation 
and, consequently, in the amount of remaining β-catenin binding sites, among A/A, A/C and 
C/C samples. For KRAS, we examined if we could detect any difference in type of mutation. 
Glycine to valine and glycine to aspartic acid were the most frequent alterations (n=11 and 
n=13, respectively). However, no difference in type of mutation was observed among A/A, A/C, 
and C/C samples. The A/C group had the most double mutations; 38% had a mutation in both 
APC and KRAS, compared with 28% for the A/A cases and 16% for the C/C cases. However, this 
difference was not significant. 
p53 and smad4 immunohistochemistry
Not many target genes on chromosomes 8q, 13q, 17p, 18q and 20q have been unequivocally 
identified. However, the role of p53 on 17p and SMAD4 on 18q has been amply documented 







are targeted by these chromosomal aberrations as well. Because reliable immunohistochemis-
try was available, we did p53 and SMAD4 immunohistochemical staining on tissue microarrays 
and correlated the findings to allelic loss status. Although 17p loss frequency was only sig-
nificantly different between the A/A and C/C tumors, aberrant p53 staining (25-100% positive 
nuclei, indicative for a mutation) was significantly increased in the A/C group compared with 
the A/A group (29% versus 5%, p = 0.022) and in the C/C group compared with both the A/C 
and A/A groups (63% versus 29%, p = 0.006 and 63% versus 5%, p < 0.001, respectively; Table 
2). In addition, significantly more aberrant staining was observed in the A/C group with high-
grade dysplasia compared with low-grade dysplasia (46% versus 0%, p < 0.001). For SMAD4, 
we assessed both the percentage of down-regulation and complete loss of protein expres-
sion. Down-regulation of SMAD4, as well as complete loss of SMAD4, were both significantly 
increased in the A/C cases when compared with the A/A cases (74% versus 48%, p = 0.04 and 
18% versus 0%, p = 0.011, respectively), and complete loss of SMAD4 was different between 
C/C and A/A cases (41% versus 0%, p < 0.001; Table 2). Both down-regulation and complete loss 
of SMAD4 expression were correlated with 18q loss (p = 0.018, p = 0.011, respectively). 
association of chromosomal aberrations to clinicopathologic features
We investigated whether several clinicopathologic markers were associated with chromosomal 
aberrations. The malignant tumors were significantly smaller than the pure adenomas (mean 
diameter 4.6 versus 6.3 cm, p = 0.032); however, the total number of aberrations, or the amount 
of the five malignant aberrations, did not correlate with tumor size. Furthermore, samples from 
different T stages were compared. We compared 10 T2 carcinomas with 25 T1 carcinomas. No 
significant differences were observed between these groups in total chromosomal instability 
or malignant aberrations. Nine cases with local recurrences were compared with those without 
recurrences. However, no significant differences were observed. Three samples had lymph 
node metastasis, but this number was too small to make any comparisons.
systematic comparison of adenoma and carcinoma tissue in the same lesion
Figure 1 shows a systematic comparison between the adenoma and carcinoma fraction 
of single cases for all genomic aberrations. Most data points are slightly above the x=y line, 
indicating that carcinoma fractions have slightly more aberrations than the corresponding 
adenoma fractions. Correlation coefficients between adenoma and carcinoma fractions were 
0.229 (p =0.180) and 0.516 (p =0.001) for the total number of aberrations and the five “malig-
nant” aberrations, respectively. The adenoma fractions with low-grade dysplasia showed fewer 
aberrations than the adenoma fractions with high-grade dysplasia; however, this difference 
was not significant. Four carcinoma fractions (11%) showed the same number of aberrations as 
their corresponding adenoma fraction, whereas 47% showed one to five extra events, and 28% 
showed more than five extra events in the carcinoma fraction. (Figure 1A) For five cases (14%), 
the adenoma fraction contained more aberrations than its corresponding carcinoma fraction.
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Figure 1B compares the occurrence of the five malignant aberrations between the adenoma 
and carcinoma fraction in the same lesion. In 42% of the adenoma fractions, two or more 
malignant events were identified. In 11 cases (31%), the amount of malignant events was 
identical in the adenoma and carcinoma fraction of one tumor. In 25% of all cases, one extra 
binding sites are retained. Albuquerque et al. (30) posed that
the position and type of the second hit on APC depends on the
localization of the first hit. Patients with the first mutation
around codon 1300 acquire the second hit by allelic loss,
whereas patients with a first mutation elsewhere acquire
truncating mutations within the mutation cluster region rather
than loss/LOH. The amount of remaining h-catenin binding
sites might lead to a different biological behavior of the
tumors. For KRAS , the type of mutation was also suggested to
be of significance. In a large data set, the valine alteration
was correlated with shorter survival in relation to other
mutations (31).
In the pure adenomas, we observed high percentages of APC
and KRAS mutations (61% and 53%, respectively), comparable
with frequencies in the A/C (62% and 67%) and C/C tumor
fractions (50% and 46%; Table 2). For APC , we examined
whether patients with 5q retention had other types of APC
mutations compared with cases with 5q LOH/loss. In the cases
with 5q LOH/loss, we observed that 64% had an APC
mutation, whereas cases with 5q retention showed a frequency
of 52% (not significant). There was no difference in the type of
mutation and, consequently, in the amount of remaining
h-catenin binding sites among A/A, A/C, and C/C samples. For
KRAS, we examined if we could detect any difference in type of
mutation. Glycine to valine and glycine to aspartic acid were
the most frequent alterations (n = 11 and 13, respectively).
However, no difference in type of mutation was observed
among A/A, A/C, and C/C samples. The A/C group had the
most double mutations; 38% had a mutation in both APC and
KRAS compared with 28% for the A/A cases and 16% for the
C/C cases. However, this difference was not significant.
p53 and SMAD4 immunohistochemistry. Not many target
genes on chromosomes 8q, 13q, 17p, 18q, and 20q have been
unequivocally identified. However, the role of p53 on 17p and
SMAD4 on 18q has been amply documented in the tumori-
genesis of colorectal cancer (32–35). Nevertheless, we cannot
rule out completely that other genes are targeted by these
chromosomal aberrations as well. Because reliable immuno-
histochemistry was available, we did p53 and SMAD4
immunohistochemical staining on tissue microarrays and
correlated the findings to allelic loss status. Although 17p loss
frequency was only significantly different between the A/A and
C/C tumors, aberrant p53 staining (25-100% positive nuclei,
indicative for a mutation) was significantly increased in the A/C
group compared with the A/A group (29% versus 5%,
P = 0.022) and in the C/C group compared with both the
A/C and A/A groups (63% versus 29%, P = 0.006, and 63%
versus 5%, P < 0.001, respectively; Table 2). In addition,
significantly more aberrant staining was observed in the A/C
group with high-grade dysplasia compared with low-grade
dysplasia (46% versus 0%, P = 0.001). Aberrant p53 staining
was correlated with 17p loss (P < 0.001). For SMAD4, we
assessed both the percentage of down-regulation and complete
loss of protein expression. Down-regulation of SMAD4 as well
as complete loss of SMAD4 were both significantly increased in
the A/C cases when compared with the A/A cases (74% versus
48%, P = 0.04, and 18% versus 0%, P = 0.011, respectively),
and complete loss of SMAD4 was different between C/C and
A/A cases (41% versus 0%, P < 0.001; Table 2). Both down-
regulation and complete loss of SMAD4 expression were
correlated with 18q loss (P = 0.018 and 0.011, respectively).
Association of chromosomal aberrations to clinicopathologic
features. We investigated whether several clinicopathologic
markers were associated with chromosomal aberrations. The
malignant tumors were significantly smaller than the pure
adenomas (mean diameter, 4.6 versus 6.3 cm; P = 0.032);
however, the total number of aberrations, or the amount of the
five malignant aberrations, did not correlate with tumor size.
Furthermore, samples from different T stages were compared.
We compared 10 T2 carcinomas with 25 T1 carcinomas. No
significant differences were observed between these groups in
total chromosomal instability or malignant aberrations. Nine
cases with local recurrences were compared with those without
recurrences. However, no significant differences were observed.
Three samples had lymph node metastasis, but this number
was too small to make any comparisons.
Fig. 1. A and B, all 36 adenoma-carcinoma pairs are plotted against each other.
X axis, adenoma fraction;Y axis, matching carcinoma fraction. Respectively, the
amount of all aberrations (A) and the five malignant events (B) are shown. A, the
degree of dysplasia for the adenoma fraction is indicated (white, low-grade
dysplasia; black , high-grade dysplasia). Numbers in the plot indicate the sample ID.
B, several pairs coincide in the same data point. For cases 8, 17, 18, and 36, no
carcinoma fraction was analyzed (seeTable1), and for these samples, we compared
the adenomawith low- versus high-grade dysplasia. For samples 14 and 24, the
adenoma fraction with low-grade dysplasia was plotted.
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Y axis, matching carcinoma fraction. Respectively, the amount of all aberrations (A) and the five malignant 
events (B) are show . A, the egree of dysplasia for the ad noma fraction is indicated (white, low-grade 
dysplasia; black, high-grade dysplasia). Numbers in the plot indicate the sample ID. B, several pairs coincide 
in the s me data point. For cases 8, 17, 18 and 36, no carcinoma fraction was analyzed (see Table 1), and for 
these samples, we compared the adenoma with low- versus high-grade dysplasia. For samples 14 and 24, 







Table 3. Distribution of genomic alterations over the chromosomes in adenoma and carcinoma fractions 
of single lesions (n=36).
Chromosome
Aberrations present in 
both fractions





not in carcinoma fraction
1p 10 6 5
1q 4 0 1
2p 1 1 0
2q 2 1 0
3p 1 3 2
3q 0 1 0
4p 3 4 3
4q 4 5 1
5p 0 4 2
5q 12 4 4
6p 5 7 2
6q 3 4 1
7p 8 3 0
7q 7 4 1
8p 4 9 2
8q 5 8 2
9p 2 4 1
9q 3 3 2
10p 1 5 1
10q 2 5 2
11p 0 2 0
11q 1 2 1
12p 7 4 2
12q 7 4 1
13q 9 13 1
14q 2 6 1
15q 3 7 1
16p 2 4 1
16q 3 3 2
17p 10 5 3
17q 5 0 5
18p 10 10 2
18q 11 14 2
19p 3 3 0
19q 1 5 0
20p 7 7 2
20q 9 9 2
21q 4 4 1
22q 6 3 2
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malignant event was detected in the carcinoma fraction, whereas in 33% two or more extra 
malignant events were detected. In four cases (11%), the adenoma fraction contained more 
malignant aberrations than the carcinoma fraction. For cases with more aberrations in the 
adenoma than in their carcinoma counterparts, we determined if data were in accordance with 
immunohistochemistry. For instance, in case 24, the adenoma fraction showed loss of 18q and 
reduced SMAD4 protein expression, whereas the carcinoma fraction showed 18q retention and 
a normal SMAD4 staining pattern. In the other samples, immunohistochemistry also confirmed 
chromosomal aberrations.
Table 3 shows the distribution of the genomic changes over the chromosomes. As expected, 
the malignant aberrations were the most common “progression” events, as these had the 
highest frequency in the carcinoma fractions, while the corresponding adenoma fractions 
did not show this event. 13q and 18q were especially strongly increased; in 13 and 14 cases, 
respectively, the carcinoma fraction contained this event in contrast to the adenoma fraction. 
The other extra events in the carcinoma fractions did not involve specific chromosomes, as the 
random distribution of events over the chromosomes shows.
intratumor heterogeneity analysis in tissue biopsies
For the clinical application of chromosomal instability profiling, accurate analysis of preopera-
tive tissue biopsies is essential. To mimic these biopsies, we investigated three postoperative 
biopsies for each tumor and estimated how representative these biopsies are for the tissue 
sample because intratumor heterogeneity is a well-known phenomenon in colorectal cancer. 
Three different biopsies were postoperatively taken ex vivo from five pure adenomas and 13 
carcinomas at random positions from the surface of the tumor and analyzed with SNP arrays 
(Table 1). Figure 2A shows genome wide chromosomal aberrations in the different biopsies and 
their corresponding adenoma or carcinoma fraction.
Roughly the same pattern of aberrations is seen in the different biopsies and the corresponding 
tumor fraction of the same patient. The number of “malignant” aberrations for all three biopsies, 
and the adenoma and carcinoma fractions per patient, is comparable for most cases. (Figure 
2B) In 3 out of 18 (17%) tumors (cases 16, 30 and 54), the amount of “malignant” aberrations 
differed considerably between the biopsies and the tumor fractions, whereas in the majority 
of cases (15 out of 18, 83%) the biopsies showed one different “malignant” aberration at most. 
We hypothesized that the biopsy with the largest number of chromosomal aberrations is 
representative for the tumor. Correlation coefficients for the number of total aberrations and 
for the number of “malignant” aberrations between that biopsy and the corresponding tissue 
fraction were 0.660 (p =0.003) and 0.807 (p <0.001; Figure 2C), respectively (biopsies contain-
ing adenoma tissue were compared with adenoma fractions, and carcinoma biopsies were 
compared with carcinoma fractions). We simulated the effect of taking, at random, one or two 
biopsies (instead of three). Taking only one biopsy resulted in a lower correlation, whereas the 







Fig. 2. A to C, overview of the 5 pure adenomas and the13 adenoma carcinoma pairs fromwhich three biopsies per tumor were analyzed.We show the three biopsies per
tumor, the adenoma fraction, and the carcinoma fraction, respectively. Numbers on the X axis indicate the sample ID, whole tumor fractions are indicated by large squares, and
biopsies are indicated by small squares (white, adenoma tissue; black , carcinoma tissue). A, all different aberrations are shown for every sample and all chromosomes. Green,
gain; red, loss; yellow, copy number neutral LOH. B, amount of five malignant aberrations per tissue sample. C, the amount of the five malignant aberrations for the whole
tissue fraction (X axis) against the biopsy with the most aberrations (Yaxis) was plotted per tumor sample. Labels in the plot indicate the sample ID.
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Figure 2. A to C, overview of the 5 pure adenomas and the 13 adenoma-carcinoma pairs from which three 
biopsies per tumor were analyz d. We show the three biopsies p r tumor, the de oma fraction, and the 
carcinoma fraction, respectively. Numbers on the X axis indicate the sample ID, whole tumor fractions are 
indicated by large squares, and biopsies are indicated by small squares (white, adenoma tissue; black, carci-
noma tissue). A, all different aberrations are shown for every sample and all chromosomes. Green, gain; red, 
loss; yellow, copy number neutral LOH. B, amount of five malignant aberrations per tissue sample. C, the 
amount of five malignant aberrations for the whole tissue fraction (X axis) against the biopsy with the most 
aberrations (Y axis) was plotted per tumor sample. Labels in the plot indicate the sample ID.
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DISCUSSION
For correct preoperative staging of rectal tumors, especially large sessile adenomas eligible for 
TEM resection, it is necessary to identify those adenomas already containing an invasive focus. 
In a previous study, we found that five specific chromosomal aberrations could clearly discrimi-
nate sessile adenomas from carcinomas. 12 Moreover, in adenoma fractions from cases with a 
carcinoma, twice the amount of such “malignant” aberrations was observed, as compared with 
pure adenomas. In the present study, we analyzed the adenoma and carcinoma fractions of 36 
rectal tumors and found that two or more malignant events are present in 46% of the adenoma 
fractions and that the increase in malignant aberrations in adenoma to carcinoma progression 
was relatively small. Intratumor heterogeneity analysis showed that it is essential to analyze 
multiple biopsies for a correct assessment of chromosomal instability patterns. The Vogelstein 
progression model for colorectal tumorigenesis, proposed in 1990 and adapted in the years 
after, has been addressed by many other studies. 20, 36-38 We now seek to use such data for 
clinical decision making. Our study showed that three of the five malignant events (gain of 13q 
and 20q and loss of 18q) were already abundant and significantly increased in rectal adenoma 
fractions of carcinoma cases compared with pure adenomas. The two other malignant events 
(8q gain and 17p loss) were not significantly changed, but percentages were increased. Further-
more, 17p loss was related to aberrant nuclear staining for p53 using immunohistochemistry, 
which was significantly different in adenomas with a carcinoma focus versus pure adenomas. 
Loss of 18q and SMAD4 immunohistochemistry showed an identical relationship. The relative 
additional amount of chromosomal aberrations in the transition from adenoma to carcinoma 
was most often equal in cases with a limited amount of adenomatous aberrations to those with 
a high amount of such events.
Hermsen et al. described seven cancer-associated events (loss of 8p, 15q, 17p and 18q and 
gain of 8q, 13q and 20q) that were associated with both carcinomas and adenoma fractions 
of carcinomas. 15 In addition, they found that these chromosomal abnormalities occurred in 
specific combinations of a few abnormalities rather than as a mere accumulation of events. 
We did not identify a specific combination of events but found that most carcinomas have at 
least two of the five malignant events. In addition, we identified gain of 19q and loss of 8p, 14q, 
and 15q as later events in carcinoma progression, as these were increased in the carcinoma 
fractions (C/C) compared with the adenoma fractions (A/C). These regions are, in part, similar 
to the results of Diep et al, who reported deletion of 8p and 14q and gain of 1q and 19q as late 
events that correlated with metastasis in a meta-analysis of 859 colorectal cancers. 11
SNP array analysis of three different ex vivo core biopsies per tumor showed a large degree 
of intratumor heterogeneity. Hence, it is essential to analyze several tumor fractions per 
patient for an accurate assessment of genetic changes. Athough intratumor heterogeneity is a 
well-studied phenomenon in CRC, our study is the first to assess genome wide heterogeneity 







heterogeneity in 90% of early colorectal cancers, a percentage that corresponds to our data. 20 
In addition, Baisse  found heterogeneity in 67% of colorectal cancer. 40 Studies in colorectal and 
other cancers showed that accumulation of clonal diversity is a fundamental principle in cancer 
progression. 41-43 In our study, less heterogeneity was present when only the five malignant 
aberrations were tested. Moreover, a good correlation was established between the biopsy 
with the most aberrations per patient and the corresponding adenoma or carcinoma fraction. 
In spite of the observed heterogeneity, it seems that three biopsies per tumor can reliably 
assess the chromosomal aberrations in rectal tumors. 
Surprisingly, some adenoma fractions showed more aberrations than their carcinoma counter-
parts. Likewise, several biopsies contained other or more aberrations than their correspond-
ing tumor fraction. This interesting finding can be explained by different factors. First, tumor 
heterogeneity might be a reason; the carcinoma fraction of such a case might have arisen from 
a different tumor clone than the adenoma fraction studied. The fact that four cases showed 
either APC or KRAS mutations in the adenoma fraction and not in the carcinoma fraction also 
suggests that the carcinoma did not arise from the adenoma clone. Consistent with our findings, 
Zauber et al. found a difference between the adenoma and carcinoma portion of tumors with 
regard to the KRAS gene in 24% of 37 neoplasms. 44 Second, it was frequently observed that 
a carcinoma fraction had a larger stromal involvement and thus a somewhat lower tumor cell 
percentage than the adenoma fraction. Although a lower tumor cell percentage might make it 
more difficult to depict chromosomal aberrations, most aberrations seemed very reproducible. 
However, with too many contaminating stromal cells, a certain chromosomal aberration might 
be present in too few cells to be detected by current techniques. Laser capture microdissection 
might offer a solution for research, but is not feasible for a clinical application. 
A recent study showed that retention of chromosome 5q correlated with liver metastasis in 
colorectal cancer. 45 The authors found that tumors with 5q deletion (loss or LOH) have a differ-
ent type of APC mutation than cases with 5q retention. Cases with 5q deletion usually have one 
APC allele affected by a mutation, usually leaving one or two β-catenin binding sites, whereas 
cases with retention usually have two different APC mutations. 30 This can lead to differences 
in residual β-catenin activity, which in turn can show an effect on the neoplastic process. We 
did not detect any significant difference between cases with 5q retention versus 5q LOH/loss 
regarding APC mutations in the mutation cluster region. However, we analyzed only the muta-
tion cluster region of APC, starting at codon 1284. If mutations occurred before the mutation 
cluster region, this would lead to loss of all β-catenin binding sites in one allele, as is probably 
the case in the samples with 5q retention.
As a large proportion of presumed sessile rectal adenomas seem to identify postoperatively 
as carcinomas, there is a need for additional preoperative tests. Most carcinomas in this study 
were preoperatively classified as adenomas; thus, a TEM was done. In the majority of carcinoma 
cases, preoperative and ex vivo core biopsies contained adenoma tissue, indicating that it is dif-
ficult to obtain a correct preoperative diagnosis using standard histopathology. Interestingly, 
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15 out of 36 (42 %) adenoma fractions of carcinoma cases had two or more malignant aber-
rations, indicative of malignancy.  Aberrant p53 and SMAD4 immunohistochemical staining 
correlated with 17p and 18q loss, respectively, and were both increased in adenoma fractions 
of carcinomas in contrast to pure adenomas. Such p53 immunohistochemistry showed an even 
better discrimination between pure adenomas and adenoma fractions of carcinoma cases than 
17p loss, indicating that some cases might have two somatic mutations in the p53 gene, instead 
of one mutation combined with chromosomal loss. However, we cannot exclude that other 
genes might be targeted by the loss. For chromosome 8q, 13q and 20q gain, the target genes 
are largely unknown, although a prime target on 8q might be the cMyc gene, for example. 
BRCA2, Rb and other tumor suppressor genes locate on chromosome 13q. Although 13q loss is 
observed in most cancer types, this chromosome usually shows gain in colorectal cancer. Earlier 
observations indeed showed increased copy numbers of one Rb1 allele, and increased levels of 
Rb mRNA and protein expression in CRC. 46-48 The role of Rb in colorectal cancer development 
is thus not clear. Currently we are integrating gene expression analysis with the obtained SNP 
data in order to study the effect of chromosomal aberrations on the transcriptional level. 
Our ex vivo biopsy analysis showed that the analysis of small biopsies is feasible because 
the chromosomal aberrations were reliably identified. Additionally, biopsies were taken at 
the surface of the tumor, just as in the preoperative situation. The five chromosomal regions 
and immunohistochemistry for p53 and SMAD4 should now be evaluated on a large series of 
multiple preoperative biopsies. However, reservations may exist to the application of the above 
approach, given that some adenomas tend to harbor more aberrations than their carcinoma 
counterparts. After validation studies, these methods can hopefully be added to future histo-
logical analysis and imaging methods, possibly leading to improved rectal tumor staging. 
In conclusion, adenoma fractions of rectal carcinoma cases show a high degree of chromo-
somal instability and have a relatively small increase in genomic alterations in their transition to 
carcinomas. The occurrence of specific chromosomal events could possibly be used to predict 
the malignant behavior of sessile rectal adenomas. The analysis of several biopsies per patient 
revealed a large degree of intra-tumor heterogeneity, but when three biopsies per tumor are 
analyzed, most aberrations are reliably identified. 
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INTRODUCTION
Rectal cancer affects over 10 000 new patients and causes 4700 deaths each year in the United 
Kingdom. Introduction of screening programs will increase the incidence of T1-2 rectal can-
cers.1 To avoid the morbidity of radical surgery (RS), local excision (LE) of rectal cancer is being 
applied increasingly 2, but controversy remains in which stages LE is justified. In general, in T2 or 
more invasive rectal cancers, LE is only considered a valid option in palliative settings because 
of the high rate of local recurrences (LR) and reduced survival compared to RS.2 In T1 rectal 
cancer only, there might be a role for LE with curative intent. Nevertheless, oncologic outcome 
is conflicting, with LR rates ranging from 6 to 18 per cent and varying survival. 3-7
Nowadays, transanal endoscopic microsurgery (TEM) is considered method of choice when 
treating rectal tumors.8 It is a modification of local excision that greatly improves accessibility, 
visibility and precision of resection thereby enabling microscopic radical excision of tumors 
located throughout the entire rectum.9 After RS for rectal cancer, microscopic positive excision 
margins (R1) are negative predictors of outcome.10 In contrast, if with TEM T1 rectal cancers 
are excised with a microscopic negative excision margin of 2 mm or more (R0), survival is 
comparable to RS but LR rates up to 24% have still been reported.11 Several authors therefore 
questioned the role of LE, including TEM, for all T1 rectal cancers, as survival in recurrent tumors 
is diminished.12-14
A distinction between low- versus high risk T1 rectal cancer has been proposed, to predict 
which tumors are likely to recur or not following TEM.15 The distinction is based on basic histo-
pathological criteria, which are differentiation grade, lymph vessel invasion and blood vessel 
invasion. 16 Also depth of invasion into the submucosa and tumor budding were identified as 
independent prognostic features. 17-19 However, these features have been challenged and con-
sensus regarding low- versus high-risk criteria in T1 rectal adenocarcinomas is still lacking.20, 21
To expand evidence on low- versus high-risk T1 rectal cancer, with respect to LR, in this study 
we try to identify predictive histopathological features in a selected group of T1 rectal cancers 
treated with TEM only. Ultimately this may lead to tailor treatment selection in individual rectal 
cancer patients.
PATIENTS AND METHODS
From a prospective database, containing over 700 patients treated with TEM in a teaching 
hospital, a subset of 84 eligible patients was identified. Patients with T1 rectal cancer, treated 
with TEM between January 1996 and December 2008, without (neo-) adjuvant treatment, in 
which no completion RS was performed, were considered eligible. An excision margin of 2 
mm or more was a prerequisite, and only those patients were considered suitable for intensive 







already been published.11 Our hospital acts as a tertiary referral center for TEM. A substantial 
proportion of patients was referred from other hospitals following snare polypectomy, in 
whom excision margin was uncertain, for removal of the scar with TEM. A total of 62 patients 
of whom the specimens of the primary tumor could be re-evaluated, containing an invasive T1 
carcinoma, were included in the present study. The group consisted of 27 females and 35 males 
with a mean age of 69 years (range 44-92). Follow up was according to the Dutch guidelines on 
rectal cancer with additional rigid rectoscopy and endorectal ultrasound (ERUS) every 3 months 
the first 2 years, and every 6 months thereafter for the detection of a LR. Magnetic resonance 
imaging (MRI) of the lesser pelvis was introduced as a part of the follow-up protocol during the 
study period and is routinely performed at 12, 24 and 36 months following TEM. Mean follow 
up of the entire group was 53 months (range 6-126). In case a LR was suspected a histological 
confirmation was obtained by biopsies.
In all patients a renewed histopathological evaluation was performed by two independent 
pathologists (EZ, JM), blinded to clinical outcome. All tumor features were scored according 
to predefined criteria (Table 1). Features assessed were specimen- and tumor area, maximum 
tumor size, size of invasive carcinoma and ratio of invasive carcinoma. Also tumors were scored 
as high- or low-risk, according to accepted criteria (differentiation grade, lymph vessel invasion 
(LVI) and blood vessel invasion (BVI)). Furthermore, distance from the deepest invasive front to 
the muscularis propria was measured in mm and submucosal invasion depth, differentiating 
between deep and superficial submucosal invasion was scored. We scored tumors as superficial 
if only the upper two thirds of the submucosa was invaded (Sm1 and 2 according to Kikuchi) 
and we scored the tumor as deep if the lower one third of the submucosa was invaded (Sm3). 
The reason for this simplification was that in our series the exact measurement of Sm1-3 was 
not possible due to secondary tissue changes, such as exophytic tumor growth that could affect 
normal tissue dimensions of the submucosa. Finally we scored for the presence of so-called 
tumor budding. Tumor budding is defined as isolated cancer cells or small cell clusters (< five 
cells) at the advancing edges of the invasive front of the cancer. 22 Positivity for budding was 
scored when there were > five buds per 20x power field.
All statistical analyses were performed with the Number Cruncher Statistical System 2001 
(NCSS Statistical Software, Kaysville, UT, USA). Statistical analysis of categorical variables was 
performed on cross-tables using the Pearson 2 test. The Kaplan-Meier method was used to 
estimate survival probabilities and these were compared using the log rank test. A p-value of < 
0.05 was considered significant.  
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RESULTS
Patient and tumor characteristics are depicted in Table 2. Overall recurrence rate at three years 
was 28%. (Figure 1a) Mean maximum tumor size in non-recurrent tumors was 3 cm (range 
0.5-8.5), compared to 5.1 cm in recurrent tumors (p < 0.001). Mean size of the invasive focus 
was comparable in both groups (nine mm). LR rates at 1, 2 and 3 years, according to maximum 
tumor size, are shown in Table 3. A cut-off value of 3 cm proved to be of predictive value, with 
LR-rates at three years in tumors larger than 3 cm of 39%, versus 16% in tumors of 3 cm and 
smaller (p < 0.03; Figure 1b).
Of nine high-risk tumors, according to accepted criteria (poor differentiation and/or LVI and/or 
BVI), three recurred (33%), whereas of 53 low-risk tumors 16 recurred (30%; Table 2). This proved 
Table 1.  Definitions of the criteria used for the histopathological evaluation of the H&E stained slides of 
the TEM resection specimens. These criteria were applied to the slide that showed the deepest infiltration 
of the tumor.
Tumor feature Predefined criteria
Specimen area Maximum length x maximum width of specimen, measured after fixation on 
a cork board
Tumor area Maximum length x maximum width of tumor, measured after fixation of the 
specimen on a cork board
Size of invasive carcinoma Maximum size of part that is truly of carcinogenic differentiation either with 
invasion in the tunica propria and a cribriform growth pattern (C1) or with 
invasion through the muscularis mucosae (C2)
Percentage carcinoma The percentage of the entire lesion removed by TEM that is truly of 
carcinogenic differentiation either with invasion in the tunica propria and 
a cribriform growth pattern (C1) or with invasion through the muscularis 
mucosae (C2).
Tumor grade Tumor grade is determined by the percentage of the lesions that shows 
formation of gland-like structures. 
-Well differentiated (grade I): glandular structures in >95% of the lesion
-Moderate differentiated (grade II): glandular structures in 50-95% of the 
lesion
-Poor differentiated (grade III): glandular structures in 5-50% of the lesion
-Undifferentiated: glandular structures in <5% of the lesion
Lymph vessel invasion Invasion in lymph vessel-like structures outside the primary lesion
Blood vessel invasion Invasion in blood vessel-like structures outside the primary lesion
Invasion depth (mm) The invasion depth is measured as the distance between the deepest 
infiltrating part of lesion and the muscularis propria in millimeters
Invasion classification The invasion depth is classified as:
- Deep: when the lesion infiltrates more than 2/3 of the distance between 
muscularis mucosae and the muscularis propria. 
- Superficial:  when lesion infiltrates less than 1/3 of the distance between 
muscularis mucosae and the muscularis propria
Budding Budding is defined as an isolated single cancer cell and a cluster composed 
of fewer than five cancer cells. These scattered foci are observed in the 







to differ non-significantly. Also when combining tumor size with accepted high-risk-criteria, 
there were no significant differences in LR rates between these combination groups.
Submucosal invasion depth and budding were of no significant predictive value either, although 
the latter almost reached statistical significance. To incorporate all potentially important pre-
dictive variables in further analysis, we combined tumor size with submucosal invasion depth, 
budding and a combination of both. The combination of maximum tumor size and submucosal 
Table 2. Patient and tumor characteristics.
Non-recurrent Recurrent p-value
Number of T1 rectal carcinomas 43 19
Age (range) 68 (44-92) 69 (50-84) NS
Female: Male 18:25 9:10 NS
Post snare coagulation 10 (23%) 3 (16%) NS
















Mean specimen area in cm² (range) 19 (2.25-63) 38 (5-84) p < 0.001
Mean tumor area in  cm² (range) 11 (0.5-56) 34 (2.25-156) p < 0.001
Mean maximum tumor size in cm (range) 3 (0.5-8.5) 5.1 (1.5-9) p < 0.001
Mean invasive carcinoma diameter in mm (range) 9 (1-22) 9 (0.3-17) NS
















































Numbers are absolute unless otherwise specified. NS= not significant; Low-risk= well or moderately dif-
ferentiated, no LVI or BVI; High-risk= poorly differentiated and/or LVI and/or BVI.
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invasion depth appeared to improve results. Patients with a tumor of 3 cm and smaller without 
deep submucosal invasion had a LR rate at three years of 7%, compared to 35% if submucosal 
invasion was deep, or maximum tumor size exceeded 3 cm (p < 0.03; Figure 1c). Combining 
tumor size and budding also improved results, with a 3-year LR-rate of 10% in tumors of 3 cm 
and smaller without budding, compared to 38% if budding was present, or maximum tumor 
size exceeded 3 cm (p < 0.02; Figure 1d).
Table 3. Local recurrence (LR) rates according to maximum tumor size at 1, 2 and 3 years.
Maximum tumor size LR-rate at 1 year LR-rate at 2 years LR-rate at 3 years p-value
≤ 4 cm 5% 5% 10% p = 0.01
> 4 cm 27% 35% 38%
≤ 3 cm 13% 13% 16% p < 0.03
> 3 cm 26% 35% 39%
≤ 2 cm 10% 10% 15% p = 0.1
> 2 cm 24% 31% 33%
Figure 1. Local recurrence rates according to tumor features.
A (top left): LR rates of all tumors
B (top right): LR rates of tumors ≤ 3 cm (solid line) and tumors > 3 cm (dotted line)
C (bottom left): LR rates of tumors ≤ 3 cm without deep submucosal invasion (solid line) and tumors ≤ 3 cm 
with deep submucosal invasion or tumors > 3 cm (dotted line)
D (bottom right): LR rates of tumors ≤ 3 cm without budding (solid line) and tumors ≤ 3 cm with budding 







However, when combining tumor size with both submucosal invasion depth and budding, the 
differences between the LR rates of the combination groups were not significant (p < 0.1).
DISCUSSION
Transanal endoscopic microsurgery (TEM) is being incorporated more and more in the surgical 
armamentarium for the removal of rectal tumors. Mainly because of worsened functional results 
after total mesorectal excision and the low rate of lymph node metastases, TEM is adapted in 
several national guidelines as a curative option in the treatment of selected T1 rectal cancers. 23 
However, despite a microscopic radical excision margin in most cases, LR rates remain as high 
as 24%. 11 As survival is limited in locally recurrent tumors following TEM, tumor selection is of 
utmost importance.14 
In our series, maximum tumor size proved to be a highly predictive feature for locoregional 
failure. This is in accordance with a review by Graham et al, in which local recurrence rates fol-
lowing LE of tumors smaller than 3 cm was 11% versus 33% in larger tumors. 24 However in 
their review this difference was not significant. In our series dividing between tumors of 3 cm 
and smaller and tumors larger than 3 cm resulted in LR rates at three years of 16% and 39% 
respectively, which was a significant difference (p<0.03). Dividing between tumors of 2 cm and 
smaller versus larger tumors, was of no additional value. 
Surprisingly, the size of the invasive focus had no influence on the LR rates after TEM. This 
unexpected finding warrants further investigation on whether spillage of viable tumor cells 
during the TEM procedure is responsible for the outgrowth of a local recurrence. Another pos-
sible explanation could be the outgrowth of untreated lymph node metastases. Other studies 
already showed that even with ERUS nodal staging in rectal cancer is difficult and probably 
inadequate. 25 Further studies should focus on these issues and the role of pre- or postoperative 
radiotherapy should be evaluated.
In the present series of 62 patients, accepted low- and high-risk criteria were of no predictive 
value. Even combining maximum tumor size with these criteria was of no value. Accepted 
low-risk tumors are well to moderately differentiated T1 rectal cancers, without (lymph-) ves-
sel invasion. 26 However, evidence is not abundant and inter- and intra-observer variability in 
scoring each of those items is not to be underestimated. 27-29 This study again questions the 
reproducibility and predictive value of basic histopathological staging.
Although submucosal invasion depth is also considered a predictive factor in T1 rectal cancer, 
18, 30 others questioned the utility of grading criteria for submucosal invasion in T1 colorectal 
carcinomas. 20, 21 In the present series submucosal invasion depth was not predictive for the 
development of LR. We also measured absolute distance from the invasive front to the muscu-
laris propria, and again this was of no influence on LR rates.
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However, when combining submucosal invasion depth with maximum tumor size the identifi-
cation of low-risk tumors was possible. In tumors smaller than 3 cm without deep submucosal 
invasion, LR rate at three years of only 7% was found, compared to a LR rate of 35% in case 
submucosal invasion was deep or tumor size exceeded 3 cm.
Recently, several other features were added as possible risk factors. Many researchers have 
already reported that dedifferentiated histology at the invasive margin (tumor budding) is sig-
nificantly associated with tumor aggressiveness in many types of cancer, including tongue 31, 
lung 32 and colorectum 33. Again however, in most series focusing on rectal cancer, the number 
of studied patients is low and results should be interpreted with caution. 19 In the present series, 
positivity for budding proved to show a trend towards significance (p = 0.16).
Combining size and budding proved to be an accurate predictive combination. In tumors of 
3 cm and smaller, without budding, at three years LR rate was 10%, whereas if budding was 
present or tumor size exceeded 3 cm LR rate was 38% was found.
Finally, in tumors of 3 cm and smaller without budding and without deep submucosal invasion, 
LR rates differed not significantly (3-years 9% versus 38%; p < 0.1), due to the low number of 
tumors in this subgroup.
How are these results to be translated into daily practice? First of all it seems obvious that in 
tumors over 3 cm, containing a T1 invasive carcinoma, although TEM is capable of obtaining 
a microscopic radical excision margin, it is questionable whether TEM is justified, with a three 
year LR rate of 39%. However, as over 60% of patients will not develop a LR, treating all these 
tumors with RS seems overtreatment. Nevertheless, it seems we can identify tumors that will 
not likely recur. In tumors of 3 cm and smaller, without deep submucosal invasion or without 
tumor budding, LR rates at three years of 7% and 10% respectively were found. These figures 
may be well accepted as a trade-off when discussing treatment options with patients, as mor-
tality after total mesorectal excision, especially in the elderly, should not be neglected. 34 
Based on our results further studies should be initiated in which more specialized histopatho-
logical evaluation by means of immunohistochemistry is incorporated. But also more tumors 
are to be analyzed to obtain more reliable results. National databases, such as in the UK and 
Scandinavia, are to be encouraged, because this may be the way to accomplish this.
In conclusion, therapeutic decision making in T1 rectal cancer is tailor made, however the real 
solution in identifying patients suitable for TEM is not present yet. When discussing all treat-
ment options in T1 rectal cancer with patients, one has to mention the realistic chances on 
developing a local recurrence following TEM. We found that tumor size alone, or in combination 
with submucosal invasion depth or tumor budding, appeared to be a significant predictive 
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SUMMARY
In rectal cancer total mesorectal excision (TME) is the gold standard. However, driven by the 
aim to avoid a permanent colostomy and the morbidity and mortality of TME, the proportion 
of patients with rectal cancer treated by local excision (LE) has increased the last two decades. 
In T1 carcinomas, LE is considered a curative option. The introduction of transanal endoscopic 
microsurgery (TEM) in 1984 was of major influence to this treatment shift. In Chapter 1 a gen-
eral introduction and a review on TEM in T1 rectal cancer are given. It is concluded that TEM 
is used with enthusiasm and with promising results, but the scientific base upon which this 
treatment regimen is build is limited.
In chapter 2 the aim of the thesis is presented.
ONCOLOGIC OUTCOME
As described in chapter 1, TEM is increasingly embraced as a curative alternative in T1 rectal 
cancer. In chapter 3 and 4 we studied the oncologic outcome of the world largest series of 
patients treated with TEM for T1 rectal cancer.
After TME for rectal cancer, processing and handling of the resection specimen is standardized, 
with margin status as a predictor for recurrence. This has yet to be implemented for TEM and 
was studied prospectively in chapter 3. Eighty patients after TEM for T1 rectal cancer were 
compared to 75 patients after TME for T1 rectal cancer. Standardized processing and handling 
of the excised specimen was mandatory after both TEM and TME. Patients were only considered 
eligible for follow-up after TEM when excision margins were negative. TEM was safer than TME 
as reflected by operating time, blood loss, hospital stay, morbidity, re-operation rate and stoma 
formation (all P < 0.001). Mortality after TEM was 0% and after TME 4%. At 5 years, both overall 
survival (TEM 75% versus TME 77%) and cancer specific survival (TEM 90% versus TME 87%) 
were comparable. Local recurrence rate after TEM was 24% and after TME 0% (P < 0.0001). It 
is concluded that, although for T1 rectal cancer TEM is a much safer technique than TME and 
survival is comparable, the local recurrence rate is substantial after TEM, despite negative exci-
sion margins after standardized pathology.
In chapter 4 the management and outcome of local recurrences following TEM for T1 rectal 
cancer is studied. During intensive follow-up, 18 patients developed a local recurrence and 
were analyzed with special emphasis on salvage surgery and survival. Median time to local 
recurrence was 10 months (range, 4 – 50). Median age at diagnosis of the recurrence was 74 
years (range, 56 - 84). Two patients were not operated because of concomitant metastatic 
disease. Sixteen patients underwent salvage surgery, without the need for extensive surgical 








mortality. Fifteen patients had a microscopic radical resection and one patient a microscopic 
irradical resection. Median follow-up of all patients was 20 months (range, 2 - 112). One patient 
had a re-recurrence and seven patients developed distant metastases. At three years, the 
overall survival was 31% and the cancer-specific survival 58%. It is concluded that for recurrent 
disease after TEM for T1 rectal cancer, salvage surgery is feasible in most patients, without the 
need for extensive surgical procedures. This may be attributable to intensive follow-up. Survival 
however is limited, mainly due to distant metastases. Tailoring selection of T1 rectal cancers and 
exploring possible adjuvant treatment strategies following salvage procedures should be the 
next steps, in order to improve survival.
QUALITY OF LIFE OUTCOME
Following TME, functional outcome is often poor with subsequent decreased quality of life. 
Besides oncologic outcome, differences between TEM and TME in functional outcome and 
quality of life may be important in therapeutic decision-making. TEM is performed via a rec-
toscope with a diameter of four centimetres, leading to scepticism regarding postoperative 
functional outcome. In Chapter 5 functional outcome and quality of life before and after TEM 
are investigated. Between 2004 and 2006, 47 patients were studied prior to and at least six 
months after TEM. Functional outcome was determined using the Faecal Incontinence Severity 
Index (FISI). Quality of life was measured using the EuroQol EQ-5D questionnaire and the Faecal 
Incontinence Quality of Life (FIQL) score. Six months after surgery, median FISI score was found 
to be decreased (p < 0.01), depicting an improvement in faecal continence. This improvement 
was most significant in tumors within seven centimetres from the dentate line (p = 0.01). From 
the patient’s perspective postoperative quality of life was found to be higher (p < 0.02). A 
significant improvement was observed in two of the four FIQLS domains (embarrassment; p 
= 0.03, lifestyle; p = 0.05). The domains of lifestyle, coping and behaviour, and embarrassment 
were correlated with the FISI (all p < 0.05). It is concluded that TEM has no deteriorating effect 
on faecal continence. Moreover, once the tumor has been excised using TEM, quality of life is 
improved.
Impact of both TEM and TME on quality of life has never been compared. In chapter 6 func-
tional outcome and quality of life following TME and TEM were studied. Fifty-four patients 
underwent TEM for T1 carcinomas. Only patients without known locoregional or distant 
recurrences were included, resulting in 36 eligible patients in whom quality of life after TEM 
was studied. The questionnaires used were the EuroQol EQ-5D, EQ-VAS, EORTC QLQ-C30 and 
EORTC QLQ-CR38. The results were compared to a sex-and age-matched sample of T+N0 rectal 
cancer patients who had undergone sphincter saving surgery by TME and a sex- and age 
matched community-based sample of healthy persons. Thirty-one patients after TEM returned 
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completed questionnaires (overall response rate 86%). Results were compared to 31 TME 
patients and 31 healthy controls. From the patients’ and social perspective quality of life did 
not differ between the three groups. Compared to TEM, significant more defaecation problems 
were seen after TME (p < 0.05). A trend towards better sexual functioning after TEM, compared 
to TME, was seen, especially in male patients, although it did not reach statistical significance. It 
is concluded that quality of life does not seem to differ following TEM and TME, but defecation 
disorders are more frequently encountered after TME. If oncologic outcome following TEM and 
TME is comparable, this difference could play a role in the choice of surgical therapy in T1 rectal 
cancer.
TUMOR SELECTION
Proper preoperative staging in rectal tumors is essential for therapeutic decision-making as 
several treatment options are at our disposal. Preoperative biopsies frequently fail to diagnose 
an invasive carcinoma and early rectal cancer is difficult to assess using CT and MRI. Endorectal 
ultrasound (ERUS) is considered a useful adjunct in preoperative staging of rectal tumors. 
However, feasibility of ERUS and its role in therapeutic decision-making in presumed rectal 
adenomas is sparsely studied. In Chapter 7 this was investigated. In patients referred for TEM, 
based on benign pathology in preoperative biopsies, ERUS was performed (N=268) and ERUS 
staging was compared to postoperative histopathological staging. In 231 tumors (86%) ERUS 
was technically feasible. Median distance from the dentate line was 11 cm in non-assessable 
tumors and 7 cm in assessable tumors (p < 0.001). In 21 tumors (9%), ERUS was not conclusive, 
mainly in recurrent tumors or after recent endoscopic manipulation (p < 0.001). With ERUS, 
in the remaining 210 tumors the rate of preoperative missed invasive carcinomas could be 
reduced from 21% to 3% (p < 0.01). If T1 carcinomas are considered suitable for TEM, with ERUS 
the proportion of undertreated tumors could be reduced from 7% to 3% (p < 0.01). However, 
based on ERUS 4% of tumors would have been overtreated, since they were overstaged as 
uT2/T3. This increase in overtreatment was also significant (p < 0.01). We concluded ERUS is 
technically feasible in almost all tumors referred for TEM and ERUS is very reliable in selecting 
tumors suitable for TEM. Therapeutic decision-making regarding local excision versus radical 
surgery based on ERUS seems valid.
In chapter 8 we investigated whether genomic analysis of biopsies could lead to the proper 
identification of a rectal carcinoma in presumed adenomas. For that purpose, chromosomal 
instability patterns were systematically compared in adenoma and carcinoma fractions of the 
same tumor to assess specific steps in rectal tumor progression. We analyzed 36 formalin-fixed, 
paraffin-embedded invasive carcinomas of which preoperative biopsies only showed adeno-








polymorphism arrays and compared with 21 previously described pure adenomas. Eighteen 
cases were included in an intratumor heterogeneity analysis. Five specific ‘‘malignant’’ events 
(gain of 8q, 13q and 20q and loss of 17p and 18q) and aberrant staining for p53 and SMAD4 
were all increased in the adenoma fractions of carcinoma cases compared with pure adenomas. 
Paired analysis revealed that 31% of the samples had an equal amount of malignant aberrations 
in their adenoma and carcinoma fractions, whereas 25% had one and 33% had two or more 
extra malignant events in the carcinoma fraction. Analysis of three core biopsies per tumor 
showed a large degree of intratumor heterogeneity. However, the number of malignant aber-
rations in the biopsy with the most aberrations per tumor correlated with the corresponding 
adenoma or carcinoma fraction (r = 0.807; P < 0.001). In conclusion, five specific chromosomal 
aberrations, combined with aberrant staining for p53 and SMAD4, can predict possible progres-
sion of sessile rectal adenomas to rectal cancer and might, after validation studies, be added 
to preoperative staging. Preferably, three biopsies should be taken from the tumor to address 
intratumor heterogeneity.
In T1 rectal cancer, discussion on high-risk criteria regarding locoregional failure following TEM 
is ongoing. Outcome may be improved if predictive tumor features for locoregional failure 
are identified. For that purpose, in chapter 9, a histopathological analysis of T1 rectal cancer 
specimens, excised with TEM, is performed. In 62 specimens, two independent pathologists, 
blinded for outcome, scored tumors according to predefined criteria. We were able to identify 
maximum tumor size as a negative predictive feature, as 39% of tumors larger than 3 cm devel-
oped a local recurrence, versus 16% of tumors smaller than 3 cm (p < 0.03). Accepted high-risk 
criteria as differentiation grade, lymph vessel invasion and blood vessel invasion were of no 
predictive value. Only when combining tumor size with submucosal invasion depth and tumor 
budding, a subgroup of low-risk tumors could be identified. In tumors of 3 cm and smaller 
without deep submucosal invasion or without budding local recurrence rates at 5 years were 
only 7% and 10% respectively. It is concluded, that tumor size alone, or in combination with 
submucosal invasion depth or tumor budding, appeared to be of significant predictive failure 
of a LR after TEM for T1 rectal cancer.
FUTURE PERSPECTIVES
With the introduction of nationwide screening regimens for colorectal cancer, the incidence of 
advanced rectal adenomas and early staged rectal cancer is expected to increase substantially. 
However, as shown in this thesis, the puzzle on TEM for T1 rectal cancer has not been solved yet. 
For obvious reasons, expansion of evidence is urgently needed.
Though survival after TEM is comparable to TME, a striking feature is the substantial rate of 
local recurrences if unselected T1 rectal cancer is treated solely with TEM. A microscopic radical 
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excision margin, confirmed with standardized handling and processing of the specimen, does 
not improve results. What is the impact of these local recurrences? Salvage surgery is possible 
with hardly any re-recurrences. From that respect, one could argue that majority of patients is 
saved the adverse effects of primary TME. On the other hand, patients with a local recurrence 
after TEM for T1 rectal cancer have impaired survival. Therefore, future research should focus on 
improving patient selection preoperative or on combining TEM with (neo-) adjuvant treatment, 
in order to decrease the local recurrence rate.
Obviously, it is essential upfront to identify rectal cancers, even if a biopsy is suggestive for an 
adenoma. Our newly developed genomic analysis might be useful. However, clinical validation 
studies are mandatory. This may be achieved on retrospective paraffin-embedded material, but 
eventually it has to be shown that genomic analysis of in-vivo biopsies is capable of identifying 
invasive rectal cancer. Further research is also to be initiated on identifying those rectal cancers 
already harbouring lymph node metastases. In our study on chromosomal instability patterns, 
one of the striking findings was the identification of node positive rectal cancers expressing a 
gain on chromosome 1q23 (p = 0.023). As with TEM a lymph node dissection is omitted, and 
local recurrences may be considered outgrowth of lymph node metastases already present at 
the time of operation, identifying those tumors already harbouring lymph node metastases 
is of additional value in therapeutic decision-making. In the end this could mean all node-
negative mobile rectal cancers can be excised with TEM, although further studies have to 
be awaited. Another way of identifying node positive rectal cancers is by means of magnetic 
resonance imaging (MRI), making use of uptake of ultrasmall superparamagnetic iron oxide 
(USPIO) particles. Early results were promising, however future results have to be awaited. 
Hopefully in the near future, with genomic analysis of biopsies in combination with improved 
diagnostic modalities as ERUS, CT-scan and MRI, proper selection of tumors suitable for TEM 
will be enabled. 
In case a carcinoma was missed pre-operatively and excised microscopically radical with TEM, 
we are not able yet to predict whether this tumor is likely to recur or not. In our series generally 
accepted risk-criteria, based on basic histological features, are too robust, although the limited 
number of TEM-treated tumors may also have contributed to our negative results. Efforts 
should be made to expand the number of tumors analyzed, perhaps by means of nationwide 
databases, as in the UK and Scandinavia. If in this way the number of TEM treated tumors is 
expanded, maybe we can finally identify predictive features, not only using basic histology but 
also by using immunohistochemical staining. 
Another strategy could be to consider adjuvant treatment. Maybe the adding of radiotherapy 
to TEM will decrease the number of local recurrences. However, if all T1 rectal cancers are to be 
irradiated, based on local recurrence rates of approximately 20 percent, 80 percent of patients 








on individual tumors. Ideally, based on (excision) biopsy material radiosensitive tumors are 
recognized and in those tumors (neo-) adjuvant radiotherapy may be added. Another strategy 
could be to consider adjuvant radiotherapy in presumed high-risk tumors, and in particular 
those larger than three centimetres. 
Finally, exploring alternative treatment regimens is of major interest. Neo-adjuvant chemo-
radiotherapy is able in obtaining a complete pathological response in approximately 15% of 
rectal cancers. In early staged tumors this number may even be higher. However, one of the 
major concerns is the discrepancy between a clinical and pathological complete response. In 
one quarter to one third of cases with a clinical complete response, the excised TME specimen 
proved to harbour vital tumor cells. Therefore, solely relying on clinical response is inadequate 
and quantification of the pathological response is a prerequisite. TEM could act as an excellence 
tool for excision of the original tumor area to objectivate the actual pathological response. Cur-
rently a multicenter trial is initiated in which mobile rectal cancer (cT1-3N0M0) is treated with 
neo-adjuvant chemoradiotherapy. In case clinical response is complete or near complete, the 
pre-treatment tattooed original tumor area is excised using TEM and pathological response is 
evaluated. If pathological response is complete (ypT0) or if remnant vital tumor cells, limited to 
the submucosa (ypT1), are present, a wait and see policy is advocated. In case of ypT2 or higher 
a completion TME is advised. Although experimental and therefore only to be done within the 
context of a trial, this regimen may identify those patients in whom rectal sparing surgery can 
be performed.
Combining all above-mentioned issues should lead us to our ultimate goal, tailor-made, 






Totale mesorectale excisie (TME) is de gouden standaard voor de behandeling van het rectum-
carcinoom. Deze geoptimaliseerde techniek heeft de resultaten sterk verbeterd. Echter, in een 
poging om de nadelige functionele stoornissen na TME te voorkomen, en om een eventueel 
(definitief ) stoma te voorkomen, neemt de proportie van patiënten die wordt behandeld mid-
dels lokale excisie (LE) het afgelopen decennium toe. De introductie van transanale endoscopi-
sche microchirurgie (TEM) heeft hier een belangrijke bijdrage aan geleverd. Bij geselecteerde 
T1 rectumcarcinomen wordt LE als curatief beschouwd. Echter de wetenschappelijke basis 
voor deze verschuiving in behandeling blijft controversieel.
In hoofdstuk 1 is middels een systematisch literatuuronderzoek de rol van LE en TEM voor het 
T1 rectumcarcinoom geëvalueerd. We moeten concluderen dat het bewijs niet geleverd is dat 
TEM een valide alternatief is voor TME. 
In hoofdstuk 2 wordt het doel van het proefschrift beschreven.
ONCOLOGISCHE UITKOMST
Zoals beschreven in hoofdstuk 1, wordt TEM als alternatief voor de curatieve behandeling van 
het T1 rectumcarcinoom beschouwd. In hoofdstuk 3 en 4 hebben we de oncologische uitkomst 
bestudeerd van werelds grootste serie van patiënten behandeld met TEM voor een T1 rectum-
carcinoom.
Een van de problemen na TEM voor T1 rectumcarcinomen is het lokaal recidief. Na TME wordt 
het preparaat gestandaardiseerd bewerkt en onderzocht, waarbij met name excisie marge een 
prognostisch belangrijke factor is voor het ontwikkelen van een lokaal recidief. Of dit ook van 
predictieve waarde is bij TEM werd prospectief onderzocht en beschreven in hoofdstuk 3. 
Tachtig patiënten na TEM voor T1 rectumcarcinoom werden vergeleken met 75 patiënten na 
TME voor een T1 rectumcarcinoom. Het studieprotocol hield onder andere gestandaardiseerd 
pathologisch onderzoek in en intensieve follow-up controles na de operatie. TEM patiënten 
werden alleen geschikt geacht voor follow-up als de excisie marge microscopisch radicaal was. 
TEM was een veiliger operatie dan TME, hetgeen werd uitgedrukt in een kortere operatieduur, 
minder bloedverlies, kortere opnameduur, minder complicaties, minder her-operaties en min-
der vaak aanleggen van een stoma (allen p < 0,01). Sterfte na TEM was 0% tegen 4% na TME. Vijf 
jaar na TEM en TME was de totale overleving (75% versus 77%) en kanker specifieke overleving 
(90% versus 87%) vergelijkbaar. Het lokaal recidief percentage was wel significant hoger na TEM 
(24% versus 0%). Ondanks het feit dat alle tumoren microscopisch radicaal verwijderd werden, 
is er dus een substantieel deel van de patiënten die een lokaal recidief na TEM ontwikkelt. In 








na TEM voor T1 rectumcarcinomen bestudeerd. Een totaal van 88 opeenvolgende patiënten 
die een TEM ondergingen voor een T1 rectumcarcinoom werden prospectief geregistreerd in 
een database. Achttien patiënten ontwikkelden een lokaal recidief gedurende de follow-up. 
Deze 18 patiënten werden bestudeerd met nadruk op resultaten na chirurgische behandeling 
middels TME voor het lokaal recidief, en overleving. De mediane tijd tot aan het ontwikkelen 
van een lokaal recidief bedroeg 10 maanden (spreiding 4-50 maanden). De mediane leeftijd 
ten tijde van diagnose van het lokaal recidief was 74 jaar (56-84 jaar). Twee patiënten werden 
niet geopereerd in verband met de aanwezigheid van uitzaaiingen welke niet genezen konden 
worden. Zestien patiënten ondergingen een TME, zonder dat er uitgebreide (multiviscerale) 
resecties noodzakelijk waren. In 44% van de patiënten werd een blijvend colostoma aangelegd. 
Geen van de patiënten overleed door de operatie. Bij 15 patiënten bleek het lokaal recidief 
microscopisch radicaal verwijderd en bij een patiënt bleek er sprake van een microscopisch niet 
radicale resectie. Mediane follow-up duur na de TME bedroeg 20 maanden (2-112 maanden). 
Een patiënt had een hernieuwd lokaal recidief en zeven patiënten ontwikkelden uitzaaiingen. 
De totale overleving 3 jaar na de TME bedroeg 31% en de kanker specifieke overleving 58%. 
Geconcludeerd werd dat het lokaal recidief na TEM voor een T1 rectumcarcinoom een belang-
rijk probleem is. Weliswaar kan met een TME lokale controle bereikt worden bij de meeste 
patiënten, wellicht toe te schrijven aan de intensieve follow-up die patiënten ondergaan na 
TEM, echter de overleving is beperkt, voornamelijk ten gevolge van uitzaaiingen. We bediscus-
siëren dat op maat gesneden selectie van T1 rectumcarcinomen en eventueel aanvullende 
behandelingsstrategieën na TME voor een lokaal recidief verder onderzocht dienen te worden 
om de resultaten te verbeteren.
KWALITEIT VAN LEVEN
Na TME kan de functionele uitkomst slecht zijn met dien ten gevolge verminderde kwaliteit 
van leven. Naast oncologische uitkomst, kan anorectale functie en kwaliteit van leven na TEM 
van belang zijn bij de keuze van behandeling. Bij TEM wordt de operatie uitgevoerd via een 
rectoscoop met een diameter van vier centimeter, hetgeen leidt tot scepsis ten aanzien van 
postoperatieve anorectale functie. In hoofdstuk 5 worden faecale continentie en kwaliteit van 
leven voor en na TEM onderzocht. Tussen 2004 en 2006 werden 47 patiënten voorafgaand en 
tenminste 6 maanden na TEM onderzocht. De faecale continentie werd vastgesteld met behulp 
van de “Faecal Incontinence Severity Index” (FISI). De kwaliteit van leven werd gemeten met 
behulp van de EuroQoL EQ-5D vragenlijst en de “Faecal Incontinence Quality of Life” (FIQL) 
score. Zes maanden na TEM bleek de mediane FISI-score afgenomen (p < 0,01), hetgeen een 
verbetering in faecale continentie impliceert. Deze verbetering trad met name op bij tumoren 
binnen een afstand van 7 cm van de linea dentata (p = 0,01). Vanuit het perspectief van de 
patiënt, was de kwaliteit van leven postoperatief hoger (p < 0,02). Een significante verbetering 
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werd waargenomen in 2 van de 4 FIQL-score domeinen: gegeneerdheid (p = 0,03) en levensstijl 
(p = 0,05). De domeinen levensstijl, het hoofd kunnen bieden/gedrag en gegeneerdheid corre-
leerden met de FISI (allen p < 0,05). De conclusie is dat TEM geen verslechtering van de faecale 
continentie geeft. Bovendien, nadat de tumor met behulp van TEM is geëxcideerd, neemt de 
kwaliteit van leven toe.
In hoofdstuk 6 is de faecale continentie en de kwaliteit van leven zowel na TEM als ook na TME 
voor het rectumcarcinoom onderzocht. De impact van beide procedures op de kwaliteit van 
leven is nog nooit vergeleken. In totaal ondergingen 54 patiënten TEM voor het T1 rectumcar-
cinoom. Alleen patiënten zonder lokaal recidief of afstandsmetastasen werden geïncludeerd, 
resulterend in 36 geschikte patiënten. De EuroQol EQ-5D, EQ-VAS, EORTC QLQ-C30 en EORTC 
QLQ-CR38 waren de vragenlijsten die werden gebruikt. De resultaten werden vergeleken 
met een qua geslacht en leeftijd vergelijkbare steekproef van patiënten met een kliernega-
tief rectumcarcinoom (T+N0), die sfincter sparende chirurgie met behulp van TME hadden 
ondergaan, en een qua geslacht en leeftijd vergelijkbare steekproef van gezonde personen 
uit de bevolking. Door 31 patiënten na TEM werden de ingevulde vragenlijsten terug gestuurd 
(antwoord percentage 86%). De kwaliteit van leven werd vergeleken met 31 patiënten na 
TME en 31 gezonde controle personen. Vanuit het perspectief van de patiënt en het sociale 
perspectief verschilde de kwaliteit van leven niet tussen de 3 groepen. Vergeleken met TEM 
werden meer defaecatie problemen gezien na TME (p < 0,05). Na TME werd, in vergelijking 
met TEM, een trend richting slechter seksueel functioneren waargenomen, in het bijzonder bij 
mannelijke patiënten. De conclusie kan zijn dat TEM en TME niet verschillen in kwaliteit van 
leven postoperatief. Wel worden vaker defaecatie problemen gezien na TME. Dit verschil kan 
een rol spleen in de keuze van chirurgische behandeling voor het T1 rectumcarcinoom.
TUMOR SELECTIE
Het is van groot belang de resultaten van TEM voor het T1 rectumcarcinoom te verbeteren. 
Een van de te volgen strategieën zou het verbeteren van de preoperatieve stadiering kunnen 
zijn. Bij rectumtumoren is het niet zelden dat preoperatieve biopten een carcinoom missen. 
Endorectale echografie (ERE) wordt als een waardevol instrument gezien bij de preoperatieve 
stadiering. Echter, technische haalbaarheid van ERE en de rol bij de keuze van chirurgische 
behandeling is zelden bestudeerd. In hoofdstuk 7 wordt dit nader onderzocht. ERE werd uit-
gevoerd bij 268 tumoren verwezen voor TEM, daar middels biopten de diagnose tubulovilleus 
adenoom (TVA) was gesteld. ERE bleek technisch haalbaar bij 231 tumoren (86%). Mediane 
afstand vanaf de linea dentata van tumoren waarbij ERE niet haalbaar bleek was 11 centime-
ter en 7 centimeter bij tumoren waarbij ERE wel technisch haalbaar bleek (p < 0,001). Bij 21 








endoscopisch was gemanipuleerd (p < 0,001). Met behulp van ERE kon het percentage gemiste 
carcinomen worden gereduceerd van 21 naar 3 procent (p < 0,01). Als ook T1 carcinomen 
geschikt worden geacht voor TEM, kon met behulp van ERE het aandeel van onderbehandelde 
tumoren worden gereduceerd van 7% naar 3% (p < 0,01). Echter, op grond van ERE zou 4% van 
alle tumoren worden overbehandeld, daar deze onterecht als uT2/T3 waren geïnterpreteerd. 
Deze toename in overbehandeling was ook significant. We concludeerden dat bij vrijwel alle 
tumoren verwezen voor TEM, ERE technisch haalbaar is en dat ERE in staat is tumoren te her-
kennen die geschikt zijn voor TEM. De keuze van chirurgische behandeling, TEM versus TME, 
kan mede worden bepaald door ERE.
In hoofdstuk 8 hebben we onderzocht of, naast ERE, biopten een invasief carcinoom kunnen 
identificeren. Hiertoe hebben we chromosomale veranderingen in paraffinemateriaal van de 
adenoom- en carcinoomdelen van tumoren, verwijderd met behulp van TEM, gepaard verge-
leken. Vroege afwijkingen die al aanwezig zijn in zuivere adenomen, progressie gerelateerde 
veranderingen (de “kwaadaardige” veranderingen) en late afwijkingen, mogelijk bepalend 
voor het verdere gedrag van carcinomen, werden achtereenvolgens geïdentificeerd. Er werden 
significant meer “kwaadaardige” afwijkingen waargenomen in de adenoom delen van carcino-
men dan in de zuivere adenomen. Zogenaamde immunohistochemische kleuringen voor twee 
kandidaat genen, p53 (gelegen op chromosoom 17p) en SMAD4 (gelegen op chromosoom 
18q) waren afwijkend in de adenoom delen van carcinomen, veelal in tegenstelling tot de 
zuivere adenomen. We konden ook specifieke progressie patronen zien in individuele tumoren, 
door systematisch de adenoom fractie met de bijbehorende carcinoom fractie te vergelijken. 
Als laatste hebben we nog gekeken naar tumorheterogeniteit, door drie biopten per patiënt 
te analyseren. Deze analyse toonde aan dat rectumtumoren in grote mate heterogeen zijn, 
wat betekent dat in een tumor te onderscheiden fracties aanwezig zijn met verschillende bio-
logische kenmerken en vaak een ander aantal chromosomale veranderingen. Er werd echter 
wel een goede overeenkomst gevonden tussen het biopt met het grootste aantal afwijkingen 
per patiënt en het bijbehorende tumordeel. Hieruit werd de conclusie getrokken dat deze 
kleine biopten een goede afspiegeling geven van de gehele tumor, maar dat voor een precieze 
vaststelling van chromosomale afwijkingen het wel noodzakelijk is om meerdere biopten per 
tumor te analyseren.
Er wordt aangenomen dat het T1 rectumcarcinoom onderverdeeld kan worden in zogenaamde 
laag- en hoogrisico tumoren. Echter, in de literatuur bestaat geen eenduidigheid ten aanzien 
van deze criteria. Resultaten na TEM voor het T1 rectumcarcinoom kunnen wellicht verbeteren 
als we histopathologische criteria kunnen identificeren die voorspellende waarde hebben ten 
aanzien van het ontstaan van een lokaal recidief. In hoofdstuk 9 hebben we dit nader onder-
zocht. Van 62 met TEM behandelde T1 carcinomen, werd door twee onafhankelijke pathologen 
het histopathologisch onderzoek herhaald en gescoord op vooraf bepaalde criteria. We konden 
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maximale tumor grootte als onafhankelijk voorspeller voor een locoregionaal recidief aantonen, 
daar bij 39% van de tumoren groter dan 3 cm een lokaal recidief ontstond, tegen 16% bij tumo-
ren van 3 cm en kleiner (p < 0,03). Geaccepteerde hoogrisico criteria als differentiatiegraad, 
lymfbaan invasie en bloedvat invasie, hadden geen voorspellende waarde in onze serie. Alleen 
door tumor grootte te combineren met submucosale invasie diepte of zogenaamde tumor 
budding, kon een subgroep van laagrisico tumoren worden geïdentificeerd. Bij tumoren van 
3 cm en kleiner zonder diepe submucosale invasie of zonder tumor budding, ontstond in 7% 
respectievelijk 10% van de tumoren een lokaal recidief.  Geconcludeerd wordt dat maximale 
tumor grootte alleen of in combinatie met submucosale invasie diepte of budding, significant 
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